WO2006037049A2 - Application of a coating on a medical device - Google Patents
Application of a coating on a medical device Download PDFInfo
- Publication number
- WO2006037049A2 WO2006037049A2 PCT/US2005/034836 US2005034836W WO2006037049A2 WO 2006037049 A2 WO2006037049 A2 WO 2006037049A2 US 2005034836 W US2005034836 W US 2005034836W WO 2006037049 A2 WO2006037049 A2 WO 2006037049A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- medical device
- catheter
- applicator
- coating
- coating substance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0009—Making of catheters or other medical or surgical tubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/22—Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/428—Vitamins, e.g. tocopherol, riboflavin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
- A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/02—Methods for coating medical devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0043—Catheters; Hollow probes characterised by structural features
- A61M25/0045—Catheters; Hollow probes characterised by structural features multi-layered, e.g. coated
Definitions
- the present invention relates to devices and techniques for applying coatings to medical devices. More specifically, to devices and techniques for applying coatings to medical devices, such as stents, balloons, and catheters.
- the coatings can be used for delivery of one or more biologically active agents, providing controlled short or long term release of biologically active components from the surface of the medical device.
- agents may be delivered to a targeted location in a human utilizing a number of different methods.
- agents may be delivered nasally, transdermally, intravenously, orally, or via other conventional methods. Delivery may vary by release rate (e.g., quick release, slow release, or biphasic release). Delivery may also vary as to how the drug is administered. Specifically, a drag may be administered locally to a targeted area, or administered systemically.
- the therapeutic agent is administered in one of a number of different ways including orally, inhallationally, or intravenously to be systemically processed by the patient.
- systemic delivery of a therapeutic agent one of which is that high concentrations of the therapeutic agent travels to all portions of the patient's body and can have undesired effects at areas not targeted for treatment by the therapeutic agent.
- large doses of the therapeutic agent only amplify the undesired effects at non-target areas.
- the amount of therapeutic agent that results in application to a specific targeted location in a patient may have to be reduced when administered systemically to reduce complications from toxicity resulting from a higher dosage of the therapeutic agent.
- An alternative to the systemic administration of a therapeutic agent is the use of a targeted local therapeutic agent delivery approach.
- the therapeutic agent is administered using a medical device or apparatus, directly by hand, or sprayed on the tissue, at a selected targeted tissue location of the patient that requires treatment.
- the therapeutic agent emits, or is otherwise delivered, from the medical device apparatus, and/or carrier, and is applied to the targeted tissue location.
- the local delivery of a therapeutic agent enables a more concentrated and higher quantity of therapeutic agent to be delivered directly at the targeted tissue location, minimizing or eliminating broader systemic side effects.
- the therapeutic agent that escapes the targeted tissue location dilutes as it travels to the remainder of the patient's body, substantially reducing or eliminating systemic effects.
- a medical device as the delrvery vehicle.
- a medical device that is used as a delivery vehicle is a stent.
- Boston Scientific Corporation sells the Taxus® stent, which contains a polymeric coating for delivering Paclitaxel.
- Johnson & Johnson, Inc. sells the Cypher® stent which includes a polymeric coating for delivery of Sirolimus.
- Targeted local therapeutic agent delivery using a medical device can. be further broken into two categories, namely, short term and long term.
- the short term delivery of a therapeutic agent occurs generally within a matter of seconds or minutes to a few days or weeks.
- the long term delivery of a therapeutic agent occurs generally within several weeks to a number of months.
- the therapeutic agent must be combined with a delivery agent, or otherwise formed with a physical impediment as a part of the medical device, to slow the release of the therapeutic agent.
- What is desired is a coated medical device wherein the coating is applied in a manner that provides a uniform consistent coating.
- the coating can be a bio-absorbable delivery agent having non-inflammatory characteristics that is able to be prepared in combination with at least one therapeutic agent for the delivery of that therapeutic agent to body tissue in a controlled release manner.
- a method and device for applying a coating to a medical device are provided that can produce uniform consistent coverage in a repeatable and controllable manner.
- an applicator for applying a coating to a medical device, the applicator features a sheath having a first end, a second end, and a lumen between the first end and the second end, the first end being flared and having a cross-sectional area greater than a cross-sectional area of at least a portion of the lumen and wherein the sheath is sized and dimensioned to fit over the medical device providing a clearance between the sheath and the medical device for receiving a coating substance for application of the coating substance to the medical device.
- a method for preparing a coated medical device. The method involves providing a medical device onto which a coating is to be applied, providing a coating substance for application onto the medical device; and applying the coating substance to the medical device using an applicator featuring a sheath having a first end, a second end, and a lumen between the first end and the second end, the first end being flared and having a cross-sectional area greater than a cross- sectional area of at least a portion of the lumen and wherein the sheath is sized and dimensioned to fit over the medical device providing a clearance between the sheath and the medical device for receiving a coating substance for application of the coating substance to the medical device.
- applying the coating substance to the medical device includes placing the applicator onto the medical device; and filling the applicator with the coating substance. In certain embodiments this may also include removing the applicator from the medical device leaving a residual coating of the coating substance on the medical device. In some embodiments, the applicator is placed onto and removed from the medical device by sliding the applicator on or off the medical device.
- applying a coating substance to the medical device includes placing the coating substance on the medical device and spreading the coating substance over the medical device by sliding the applicator over the medical device.
- the method further includes curing the coating substance on the medical device to form the coating.
- Curing generally refers to thickening, hardening, or drying of a material brought about by heat, UV, reactive gas, or chemical means.
- the method further includes the step of placing a protective sleeve over the medical device to protect the coating on the medical device.
- the medical device is a stent, balloon, or catheter.
- a stent is located on an end of a catheter for deployment by the catheter.
- a cap is provided for use in the application of a coating to a catheter.
- the cap features a section of tubing configured to fit on the end of the catheter to seal the lumen at the end of the catheter during the application of a coating.
- the cap is a cap stylet.
- the cap stylet features a stylet configured to fill a lumen of the catheter and a section of tubing attached to the stylet sized and dimensioned to be fitted on the end of the catheter to seal the lumen of the catheter.
- a method of applying a coating to a catheter includes providing a catheter having a proximal end, a distal end, and a lumen between the proximal and distal ends, providing a coating substance or application onto the catheter, providing a cap configured to fit onto an end of the catheter, placing the cap onto an end of the catheter, and applying the coating substance onto the catheter, wherein, the cap prevents coating substance from penetrating the lumen at the end of the catheter.
- the coating substance can be applied using an applicator.
- a system for use in preparing a coated catheter, the system includes a cap stylet including a stylet configured to fill a lumen of the catheter and a section of tubing attached to the stylet sized and dimensioned to be fitted on an end of the catheter to seal the lumen of the catheter; and an applicator featuring a sheath having a first end, a second end, and a lumen between the first end and the second end, the first end being flared and having a cross-sectional area greater than a cross-sectional area of at least a portion of the lumen and wherein the sheath is sized and dimensioned to fit over the medical device providing a clearance between the sheath and the medical device for receiving a coating substance for application to the medical device.
- the system may further include a protective sleeve configured to be place over the catheter to protect a coating on the catheter.
- a method of coating a catheter is provided.
- the method includes providing a catheter having a proximal end, a distal end, and a lumen between the proximal and distal ends; providing a coating substance or application onto the catheter; providing a cap stylet configured to fit onto an end of the catheter; providing an applicator featuring a sheath having a first end, a second end, and a lumen between the first end and the second end, the first end being flared and having a cross-sectional area greater than a cross-sectional area of at least a portion of the lumen and wherein the sheath is sized and dimensioned to fit over the medical device providing a clearance between the sheath and the medical device for receiving a coating substance for application of the coating substance to the medical device configured to apply a coating to the catheter; placing the cap stylet onto an end of the catheter; and applying the coating substance onto the catheter using the applicator; wherein the cap stylet prevents coating substance from penetrating the lumen at the end of the catheter.
- FIG. 1 is a diagrammatic illustration of a medical device, according to one embodiment of the present invention.
- FIG. 2 is a cross-sectional view of the medical device in accordance with one aspect of the present invention.
- FIG. 3 is a cross-sectional view of the medical device in accordance with another aspect of the present invention.
- FIG. 4 is a flow chart illustrating a method of making a coated medical device, in accordance with one embodiment of the present invention
- FIG. 5 is a flow chart illustrating a variation of the method of FIG. 4 using an applicator in accordance with one embodiment of the present invention
- FIG. 6A is a diagrammatic illustration of an applicator in accordance with one embodiment of the present invention.
- FIG. 6B is a diagrammatic illustration of an applicator in accordance with another embodiment of the present invention.
- FIG. 7 is a flow chart illustrating a variation of the method of FIG. 4 using a cap stylet in accordance with one embodiment of the present invention
- FIG. 8 is a diagrammatic illustration of a cap stylet in accordance with one embodiment of the present invention
- FIG. 9 is a flow chart illustrating a method of applying a coating to a catheter using an applicator and cap stylet in accordance with one embodiment of the present invention.
- FIG. 10 is a diagrammatic illustration of the interaction of a catheter, applicator, and cap stylet in accordance with one embodiment of the present invention.
- FIG. 11 is a flow chart illustrating a variation of the method of FIG. 4, in accordance with one embodiment of the present invention
- FIG. 12 is a flow chart illustrating another variation of the method of FIG. 4, in accordance with one embodiment of the present invention.
- FIG. 13 is a flow chart illustrating another variation of the method of FIG. 4, in accordance with one embodiment of the present invention.
- FIG. 14 is a diagrammatic illustration of a coated medical device in accordance with one embodiment of the present invention.
- An illustrative embodiment of the present invention relates to the provision of a coating on an implantable medical device.
- the coating can include a bio-absorbable carrier component.
- a therapeutic agent component can also be provided.
- the coating is not limited to a bio- absorbable carrier component or a therapeutic agent component. Rather, any variation of coating formed with application of a relatively liquid or fluent material that is desired for application to a medical device can be applied using the applicator and method of the present invention.
- the coated medical device can be implantable in a patient to affect controlled delivery of the coating to the patient, or can be for external use.
- bio-absorbable generally refers to having the property or characteristic of being able to penetrate the tissue of a patient's body.
- bio-absorption occurs through a lipophilic mechanism.
- the bio-absorbable substance is soluble in the phospholipid bi-layer of cells of body tissue, and therefore impacts how the bio-absorbable substance penetrates into the cells.
- Biodegradable is generally defined as capable of being decomposed by biological agents, or capable of being broken down by microorganisms or biological processes, in a manner that does not result in cellular uptake of the biodegradable substance. Biodegradation thus relates to the breaking down and distributing of a substance through the patient's body, verses the penetration of the cells of the patient's body tissue. Biodegradable substances can cause inflammatory response due to either the parent substance or those formed during breakdown, and they may or may not be absorbed by tissues.
- controlled release generally refers to the release of a biologically active agent in a predictable manner over the time period of weeks or months, as desired and predetermined upon formation of the biologically active agent on the medical device from which it is being released. Controlled release includes the provision of an initial burst of release upon implantation, followed by the predictable release over the aforementioned time period.
- oils With regard to the aforementioned oils, it is generally known that the greater the degree of unsaturation in the fatty acids the lower the melting point of a fat, and the longer the hydrocarbon chain the higher the melting point of the fat.
- a polyunsaturated fat thus, has a lower melting point, and a saturated fat has a higher melting point. Those fats having a lower melting point are more often oils at room temperature. Those fats having a higher melting point are more often waxes or solids at room temperature. Therefore, a fat having the physical state of a liquid at room temperature is an oil.
- polyunsaturated fats are liquid oils at room temperature
- saturated fats are waxes or solids at room temperature.
- Polyunsaturated fats are one of four basic types of fat derived by the body from food.
- the other fats include saturated fat, as well as monounsaturated fat and cholesterol.
- Polyunsaturated fats can be further composed of omega-3 fatty acids and omega-6 fatty acids. Under the convention of naming the unsaturated fatty acid according to the position of its first double bond of carbons, those fatty acids having their first double bond at the third carbon atom from the methyl end of the molecule are referred to as omega-3 fatty acids. Likewise, a first double bond at the sixth carbon atom is called an omega-6 fatty acid. There can be both monounsaturated and polyunsaturated omega fatty acids.
- Omega-3 and omega-6 fatty acids are also known as essential fatty acids because they are important for maintaining good health, despite the fact that the human body cannot make them on its own. As such, omega-3 and omega-6 fatty acids must be obtained from external sources, such as food. Omega-3 fatty acids can be further characterized as containing eicosapentaenoic acid (EPA), docosahexanoic acid (DHA), and alpha-linolenic acid (ALA). Both EPA and DHA are known to have anti ⁇ inflammatory effects and wound healing effects within the human body.
- EPA eicosapentaenoic acid
- DHA docosahexanoic acid
- ALA alpha-linolenic acid
- Oil that is hydrogenated becomes a waxy solid. Attempts have been made to convert the polyunsaturated oils into a wax or solid to allow the oil to adhere to a device for a longer period of time.
- hydro genation is a chemical reaction that adds hydrogen atoms to an unsaturated fat (oil) thus saturating it and making it solid at room temperature. This reaction requires a catalyst, such as a heavy metal, and high pressure. The resultant material forms a non-crosslinked semi ⁇ solid. Hydrogenation can reduce or eliminate omega-3 fatty acids, and any therapeutic effects (both anti-inflammatory and wound healing) they offer.
- oils and more specifically oils containing omega-3 fatty acids, have been utilized as a delivery agent for the short term uncontrolled release of a therapeutic agent, so that minimal or no curing is required.
- oils containing omega-3 fatty acids for combination with a therapeutic agent in a controlled release application that makes use of the therapeutic benefits of the omega-3 fatty acids.
- some heating of the omega-3 fatty acids to cure the oil can lessen the total therapeutic effectiveness of the omega-3 fatty acids, but not eliminate the therapeutic effectiveness.
- One characteristic that can remain after certain curing by heating methods is the non-inflammatory response of the tissue when exposed to the cured material.
- an oil containing omega-3 fatty acids can be heated for curing purposes, and still maintain some or even a substantial portion of the therapeutic effectiveness of the omega-3 fatty acids.
- the therapeutic agent combined with the omega-3 fatty acid and cured with the omega-3 fatty acid can be rendered partially ineffective, the portion remaining of the therapeutic agent can, in accordance with the present invention, maintain pharmacological activity and in some cases be more effective than an equivalent quantity of agent delivered with other coating delivery agents.
- the remaining 20% of therapeutic agent, combined with and delivered by the coating can be efficacious in treating a medical disorder, and in some cases have a relatively greater therapeutic effect than the same quantity of agent delivered with a polymeric or other type of coating.
- polymers For long term controlled release applications, polymers, as previously mentioned, have been utilized in combination with a therapeutic agent. Such a combination provides a platform for the controlled long term release of the therapeutic agent from a medical device.
- polymers have been determined to themselves cause inflammation in body tissue. Therefore, the polymers often must include at least one therapeutic agent that has an anti-inflammatory effect to counter the inflammation caused by the polymer delivery agent.
- patients that received a polymer- based implant must also follow a course of long term systemic anti-platelet therapy to offset the thrombogenic properties of the non-absorbable polymer. A significant percentage of patients that receive such implants are required to undergo additional medical procedures, such as surgeries (whether related follow-up surgery or non-related surgery) and are required to stop their anti-platelet therapy.
- FIGS. 1 through 14 illustrate example embodiments of an applicator and corresponding method for coating a medical device, along with representative coated medical device examples.
- FIG. 1 illustrates a stent 10 in accordance with one embodiment of the present invention.
- the stent 10 is representative of a medical device that is suitable for having a coating applied thereon to affect a therapeutic result.
- the stent 10 is formed of a series of interconnected struts 12 having gaps 14 formed therebetween.
- the stent 10 is generally cylindrically shaped. Accordingly, the stent 10 maintains an interior surface 16 and an exterior surface 18.
- the illustrative stent 10 is merely exemplary of a number of different types of stents available in the industry.
- the strut 12 structure can vary substantially.
- the material of the stent can also vary from a metal, such as stainless steel, Nitinol, nickel, tantalum, magnesium, and titanium alloys, to cobalt chromium alloy, ceramic, plastic, and polymer type materials.
- a metal such as stainless steel, Nitinol, nickel, tantalum, magnesium, and titanium alloys, to cobalt chromium alloy, ceramic, plastic, and polymer type materials.
- the present invention is not limited to use on stents. Instead, the present invention has application on a wide variety of medical devices. For purposes of clarity, the following description will refer to a stent as the exemplar medical device. The terms medical device and stent are interchangeable with regard to the applicability of the present invention. Accordingly, reference to one or another of the stent, or the medical device, is not intended
- FIG. 2 illustrates one example embodiment of the stent 10 having a coating 20 applied thereon in accordance with the present invention.
- FIG. 3 is likewise an alternative embodiment of the stent 10 having the coating 20 also applied thereon.
- the coating 20 is applied to the medical device, such as the stent 10, to provide the stent 10 with different surface properties, and also to provide a vehicle for therapeutic applications.
- the coating 20 is applied on both the interior surface 16 and the exterior surface 18 of the strut 12 forming the stent 10.
- the coating 20 in FIG. 2 substantially encapsulates the struts 12 of the stent 10.
- the coating 20 in both configurations is the same coating; the difference is merely the portion of the stent 10 that is covered by the coating 20.
- the coating 20 as described throughout the Description can be applied in both manners shown in FIG. 2 and FIG. 3, in addition to other configurations such as, partially covering select portions of the stent 10 structure. All such configurations are described by the coating 20 reference.
- the stent 10 includes the coating 20, which is bio-absorbable.
- Tlie coating 20 has a bio-absorbable carrier component, and can also include a therapeutic agent component that can also be bio- absorbable.
- Restenosis is a condition whereby the blood vessel experiences undesirable cellular remodeling after injury.
- the stent When a stent is implanted in a blood vessel, and expanded, the stent itself may cause some injury to the blood vessel.
- the treated vessel typically has a lesion present which can contribute to the inflammation and extent of cellular remodeling. The end result is that the tissue has an inflammatory response to the conditions.
- the stent when a stent is implanted, there is often a need for the stent to include a coating that inhibits inflammation, or is non ⁇ inflammatory, and prevents restenosis.
- these coatings have been provided using a number of different approaches as previously described in the Background.
- none of the prior coatings have utilized a bio-absorbable carrier component to create a bio-absorbable coating with suitable non-inflammatory properties for controlled release of a therapeutic agent.
- the bio-absorbable carrier component is in the form of a naturally occurring oil.
- An example of a naturally occurring oil is fish oil or cod liver oil.
- a characteristic of the naturally occurring oil is that the oil includes lipids, which contributes to the lipophilic action that is helpful in the delivery of therapeutic agents to the cells of the body tissue.
- the naturally occurring oil includes omega-3 fatty acids in accordance with several embodiments of the present invention.
- omega-3 fatty acids and omega-6 fatty acids are known as essential fatty acids.
- Omega-3 fatty acids can be further characterized as eicosapentaenoic acid (EPA), docosahexanoic acid (DHLA), and alpha- linolenic acid (ALA). Both EPA and DHA are known to have anti-inflammatory effects and wound healing effects within the human body.
- bio-absorbable generally refers to having the property or characteristic of being able to penetrate the tissues of a patient's body.
- the bio-absorbable coating contains lipids, many of which originate as triglycerides. It has previously been demonstrated that triglyceride products such as partially hydrolyzed triglycerides and fatty acid molecules can integrate into cellular membranes and enhance the solubility of drugs into the cell. Whole triglycerides are known not to enhance cellular uptake as well as partially hydrolyzed triglyceride, because it is difficult for whole triglycerides to cross cell membranes due to their relatively larger molecular size. Vitamin E compound can also integrate into cellular membranes resulting in decreased membrane fluidity and cellular uptake.
- a coating containing an antioxidant such as alpha-tocopherol may aid in preventing further damage by this mechanism.
- fatty acids and alpha-tocopherol can be used alone or in combination to provide an effective transport of a given compound to a given region or location. Both fatty acids and alpha-tocopherol are accommodated by the coating of the present invention described herein. Accordingly, fatty acids and alpha-tocopherol can be combined in differing amounts and ratios to contribute to a coating in a manner that provides control over the cellular uptake characteristics of the coating and any therapeutic agents mixed therein.
- the bio-absorbable nature of the carrier component and the resulting coating results in the coating 20 being completely absorbed over time by the cells of the body tissue. There are no break down products of the coating that induce an inflammatory response.
- the coating 20 is generality composed of fatty acids, including in some instances omega-3 fatty acids, bound to triglycerides, potentially also including a mixture of free fatty acids and vitamin E.
- the triglycerides are broken down by lipases (enzymes) which result in free fatty acids that can than be transported across cell membranes. Subsequently, fatty acid metabolism by the cell occurs to metabolize any substances originating with the coating.
- the bio-absorbable nature of the coating thus results in the coating being absorbed, leaving only an underlying delivery or other medical device structure. There is no foreign, body response to the bio-absorbable carrier component, including no inflammatory response.
- the modification of the oils from a more liquid physical state to a more solid, but still flexible, physical state is implemented through the curing process. As the oils are cured, especially in the case of fatty acid-based oils such as fish oil, cross-links form creating a gel. As the curing process is performed over increasing time durations and/or increasing temperature conditions, more cross-links form transitioning the gel from a. relatively liquid gel to a relatively solid-like, but still flexible, gel structure.
- the coating can also include a therapeutic agent component.
- the therapeutic agent component mixes with the bio-absorbable carrier component as described later herein.
- the therapeutic agent component can take a number of different forms including but not limited to anti-oxidants, anti-inflammatory agents, anti-coagulant agents, drugs to alter lipid metabolism, antiproliferatives, anti-neoplasties, tissue growth stimulants, functional protein/factor delivery agents, anti-infective agents, anti-imaging agents, anesthetic agents, therapeutic agents, tissue absorption enhancers, anti-adhesion agents, germicides, antiseptics, proteoglycans, GAG's, gene delivery (polynucleotides), polysaccharides (e.g., heparin), anti-migratory agents, pro-healing agents, ECM/protein production inhibitors, analgesics, prodrugs, and any additional desired therapeutic agents such as those listed in Table 1 below.
- Analgesics Bupivicaine, naproxen, ibuprofen, acetylsalicylic acid
- Some specific examples of therapeutic agents useful in the anti-restenosis realm include cerivastatin, cilostazol, fluvastatin, lovastatin, paclitaxel, pravastatin, rapamycin, a rapamycin carbohydrate derivative (for example as described in US Patent Application Publication 2004/0235762), a rapamycin derivative (for example as described in US Patent No. 6,200,985), everolimus, seco-rapamycin, seco-everolimus, and simvastatin.
- the resulting coating can be bio-absorbable if the therapeutic agent component is also bio- absorbable.
- the present invention relates to coating a medical device with a coating.
- the coating is formed of at least two primary components, namely a bio-absorbable carrier component and a therapeutic agent component.
- the therapeutic agent component has some form of therapeutic or biological effect.
- the bio-absorbable carrier component can also have a therapeutic or biological effect.
- the bio-absorbable carrier component is different from the conventional bio-degradable substances utilized for similar purposes.
- the bio-absorbable characteristic of the carrier component enables the cells of body tissue of a patient to absorb the bio-absorbable carrier component itself, rather than breaking down the carrier component into inflammatory by-products and disbursing said by-products of the component for ultimate elimination by the patient's body.
- anti-inflammatory drug dosages to the patient do not need to be increased to additionally compensate for inflammation caused by the carrier component, as is otherwise required when using polymer-based carriers that themselves cause inflammation.
- the present description makes use of the stent 10 as an example of a medical device that can be coated with the coating 20 of the present invention.
- the present invention is not limited to use with the stent 10.
- any number of other implantable medical devices can be coated in accordance with the teachings of the present invention with the described coating 20.
- Such medical devices include catheters, grafts, balloons, prostheses, stents, other medical device implants, and the like.
- Implantation refers to both temporarily implantable medical devices, as well as permanently implantable medical devices.
- a common requirement of stents is that they include some substance or agent that inhibits restenosis.
- the example coating 20 as described is directed toward the reduction or the elimination of restenosis.
- the coating 20 can have other therapeutic or biological benefits.
- the composition of the coating 20 is simply modified or mixed in a different manner to result in a different biological effect.
- FIG. 4 illustrates one method of making a coated medical device, in the form of the coated stent 10.
- the process involves providing a medical device, such as the stent 10 (step 100).
- a coating, such as coating 20, is then applied to the medical device (step 102).
- this basic method of application of a coating to a medical device such as the stent 10 can have a number of different variations falling within the process described.
- the stent 10 with the coating 20 applied thereon can be implanted after the coating 20 is applied, or additional steps such as curing, sterilization, and removal of solvent can be applied to further prepare the stent 10 and coating 20.
- the coating 20 includes a therapeutic agent that requires some form of activation (such as UV light), such actions can be implemented accordingly.
- applying the coating to the medical device involves using an applicator to apply the coating.
- the use of an applicator allows for application of coating having improved uniformity and coverage.
- An exemplary method of this can be seen in FIG. 5.
- the method involves providing a medical device onto which a coating is to be applied (step 202); providing a coating substance for application onto the medical device (step 204); and applying the coating substance to the medical device using an applicator (step 206).
- the method may further include the step of curing the coating substance to form a coating on the medical device (step 208).
- FIG. 6 A An exemplary embodiment of an applicator 300 can be seen in FIG. 6 A.
- the applicator 300 is formed of a sheath 302 having a first end 304, a second end 306 and a lumen 308 between the first 304 and second 306 ends.
- the first end 304 is flared and has a cross-sectional area greater than a cross sectional area of a portion of the lumen 308.
- the sheath 302 is sized and dimensioned to fit over the medical device 310, while providing a clearance between the sheath 302 and the medical device 310 for receiving a coating substance for application to the medical device 310.
- the second end 306 may also be flared and have a cross-sectional area greater than a cross- sectional area of at least a portion of the lumen 308, as can be seen in FIG 6B.
- medical devices 310 on which the applicator 300 may be used include stents and catheters.
- a coating is applied to a stent that has been positioned on the end of a catheter.
- the applicator 300 is formed of plastic but other suitable material that can be formed into the desired configuration can be used.
- the cross-section shape of the applicator is circular giving the applicator a funnel or trumpet like shape.
- Other suitable cross sectional shapes include polygonal shapes such as hexagonal, octagonal, or the like. Other possible shapes and configurations will be apparent to one skilled in the art given the benefit of this disclosure.
- the coating is applied by placing the applicator 300 onto the medical device 310 and then filling the applicator 300 with the coating substance.
- the flared nature of the first end 304 assists in providing a larger opening for receiving the coating substance and directing it onto the medical device.
- the coating substance may be placed into the applicator 300, for example, at flared first end 304, or be placed onto the medical device 310 directly.
- the coating substance is delivered using metering device, such as a syringe, so that the amount of coating, and in certain cases, dosage of therapeutic agent, can be controlled.
- the applicator 300 is configured to slide onto the medical device 310. hi other embodiments, the applicator 300 may be formed of two halves that are joined together around the medical device 310. Other possible configurations will be apparent to one skilled given the benefit of this disclosure.
- the applicator 300 can be removed.
- removing the applicator 300 is performed by sliding the applicator 300 off the medical device 310.
- the coating substance may be applied directly to the medical device 310 and the applicator 300 is then slid over the medical device 310 to spread the coating substance over the medical device 310.
- the clearance between the sheath 302 and the medical device 310 is dimensioned and sized to leave a residual coating of the coating substance on the medical device 310 as the applicator 300 is slid over the medical device 310.
- the clearance is between 0.0001 to 0.1 inches. More preferably, the clearance is between 0.001 to 0.01 inches. In certain embodiments the uniformity and coverage of such a residual coating can be improved by sliding the applicator 300 over the medical device 310 with a twisting motion.
- the coating substance is cured to form the coating on the medical device.
- Curing can be performed after the applicator has been removed, or with the applicator still in place over the medical device.
- Curing with respect to the present invention generally refers to thickening, hardening, or drying of a material brought about by heat, UV, reactive gases, or chemical means.
- a protective sleeve 314 is placed over the medical device 310 to protect the coating on the medical device 310 during further handling.
- the protective sleeve 314 is formed of plastic, and sized and dimensioned to fit over the medical device 310.
- Other suitable implementations will be apparent to one skilled in the art given the benefit of this disclosure.
- a cap such as cap stylet, may be used when applying the coating substance.
- the cap When placed on the end of a catheter, the cap prevents coating substance from penetrating the lumen at the end of the catheter.
- FIG. 7 An exemplary embodiment of such a method can be seen in FIG. 7.
- the method involves providing a catheter onto which a coating is to be applied (step 402), providing a coating substance for application onto the catheter (step 404), providing a cap configured to fit onto an end of the catheter (step 406); placing the cap onto an end of the catheter (step 408), and applying the coating substance onto the catheter (step 410).
- the cap comprises a section of tubing configured to fit on the end of the catheter to seal the lumen at the end of the catheter during the application of a coating.
- An exemplary embodiment of a cap and its interaction with a catheter can be seen in FIG. 8.
- the cap is a cap stylet 500.
- the catheter 520 has a proximal end (not shown), a distal end 522, and a lumen 524 between the proximal and distal ends.
- the cap stylet 500 features a stylet 502 configured to fill the lumen 524 of the catheter 520; and a section of tubing 504 attached to the stylet 502 sized and dimensioned to be fitted on the end of the catheter 520 to seal the lumen 524 of the catheter 520.
- the section of tubing 504 is sized to pinch fit on the end of a catheter 520.
- the cap can snap or interference fit on the end of the catheter.
- the cap stylet 500 prevents the coating substance from wicking into the lumen 524 at the end of the catheter 520 as a coating is applied. If the coating substance gets into the lumen 524 it could create an obstruction that may adversely effect the operation of the catheter 520.
- the cap stylet 500 is placed on the distal end 522 of the catheter 520, which is to be inserted into a patient, and is thus coated, hi certain embodiments wherein the whole catheter is to be coated, a cap stylet 500 can be placed on each end of the catheter 520.
- the coating can then be applied to the catheter (step 410 of FIG. 7). In certain embodiments this involves using an applicator as set forth above.
- the coating may also be applied by dip coating, spray coating, printing, wiping, electrostatic coating, brushing, painting or any means suitable for applying the coating substance.
- a protective sleeve 510 may be placed on the catheter 520 to protect the coating.
- the method includes providing a catheter (step 600), providing the coating substance for application onto the catheter (step 602), providing a cap stylet configured to fit onto an end of the catheter (step 604), providing an applicator configured to apply a coating to the catheter (step 606), placing the cap stylet onto an end of the catheter (step 608) and applying the coating substance onto the catheter using the applicator (step 610).
- a catheter 720 has a stent 710 pre-positioned on the distal end 722 of the catheter implantation in a patient.
- a cap stylet 730 is placed unto the distal end 722 of the catheter 720.
- the cap stylet 730 features a stylet 732 configured to fill a lumen 724 of the catheter 720, and a section of tubing 734 attached to the stylet 732 sized and dimensioned to be fitted on an end of the catheter 720 to seal the lumen 724 of the catheter 720.
- the applicator 740 is then slid onto the catheter 720 beyond the stent 710.
- the applicator 740 features a sheath 742 having a first end 744, a second end 746 and a lumen 748 between the first 744 and second 746 ends.
- the first end 744 is flared and has a cross-sectional area greater than a cross-sectional area of at least a portion of the lumen 748.
- the sheath 742 is sized and dimensioned to fit over the catheter 720, providing a clearance between the sheath 742 and the catheter 720 for receiving a coating substance for application to the catheter.
- the applicator 740 is filled with coating substance at the flared first end 744 using a metering device, such as a syringe, to ensure the proper amount of coating substance is applied.
- the coating substance may be applied directly to the catheter 720.
- the applicator 740 is then slid off the catheter 720 over the stent 710 and cap stylet 730 in the direction of arrow 760 using a twisting motion.
- the clearance between the sheath 742 and the catheter 720 is sized and dimensioned to leave a residual coating of the coating substance as the applicator 740 is slid over the catheter 720.
- the coating substance 750 may be cured as discussed above.
- a protective sleeve can be placed over the catheter 720 and stent 710 to protect the coating during further handling.
- FIG. 11 is a flowchart illustrating another example implementation of the method of FIG. 4.
- a bio-absorbable carrier component is provided along with a therapeutic agent component (step 810).
- the provision of the bio-absorbable carrier component and the provision of the therapeutic agent component can occur individually, or in combination, and can occur in any order or simultaneously.
- the bio-absorbable carrier component is mixed with the therapeutic agent component (or vice versa) to form a coating substance (step 820).
- the coating substance is applied to the medical device, such as a stent or catheter, to form the coating (step 830).
- the coated medical device is then sterilized using any number of different sterilization processes (step 840).
- sterilization can be implemented utilizing ethylene oxide, gamma radiation, E beam, steam, gas plasma, or vaporized hydrogen peroxide.
- sterilization processes can also be applied, and that those listed herein are merely examples of sterilization processes that result in a sterilization of the coated stent, preferably without having a detrimental effect on the coating 20.
- FIG. 12 is a flow chart illustrating one example method for forming each of the components.
- Vitamin E is mixed with a bio-absorbable carrier to form a bio-absorbable carrier component (step 910).
- a solvent is mixed with a therapeutic agent to form a therapeutic agent component (step 920).
- the solvent can be chosen from a number of different alternatives, including ethanol or N-Methyl-2-Pyrrolidone (NMP).
- NMP N-Methyl-2-Pyrrolidone
- the bio-absorbable carrier component is then mixed with the therapeutic agent component to form the coating substance (step 930).
- the solvent can then be removed with vacuum or heat.
- a surface preparation or pre-treatment 22 is provided on a stent 10. More specifically and in reference to the flowchart of FIG. 13, a pre-treatment substance or base coating is first provided (step 1010). The pre-treatment substance or base coating is applied to a medical device, such as the stent 10, to prepare the medical device surface for application of the coating (step 1020). If desired, the pre-treatment or base coating 22 is cured (step 1030).
- Curing methods can include processes such as application of UV light, heat, reactive gases, or chemical means to cure the pre-treatment 22.
- a coating substance is then applied on top of the pre-treatment 22 (step 1040).
- the coated medical device is then sterilized using any number of sterilization processes as previously mentioned (step 1050).
- FIG. 14 illustrates the stent 10 having two coatings, specifically, the pre- treatment 22 and the coating 20.
- the pre-treatment 22 serves as a base or primer for the coating 20.
- the coating 20 conforms and adheres better to the pre-treatment 22 verses directly to the stent 10, especially if the coating 20 is not heat or UV cured.
- the pre- treatment can be formed of a number of different materials or substances. Li accordance with one example embodiment of the present invention, the pre-treatment is formed of a bio-absorbable substance, such as a naturally occurring oil (e.g., fish oil).
- the bio- absorbable nature of the pre-treatment 22 results in the pre-treatment 22 ultimately being absorbed by the cells of the body tissue after the coating 20 has been absorbed.
- the pre-treatment 22 can be cured to better adhere the pre-treatment 22 to the stent 10, without losing all of the therapeutic benefits resident in the pre- treatment 22, or in the subsequently applied coating 20. Furthermore, the cured pre- treatment 22 provides better adhesion for the coating 20 relative to when the coating 20 is applied directly to the stent 10 surface. In addition, the pre-treatment 22, despite being cured, remains bio-absorbable, like the coating 20.
- the pre-treatment 22 can be applied to both the interior surface 16 and the exterior surface 18 of the stent 10, if desired, or to one or the other of the interior surface 16 and the exterior surface 18. Furthermore, the pre-treatment 22 can be applied to only portions of the surfaces 16 and 18, or to the entire surface, if desired.
- the application of the coating to the medical device can take place in a manufacturing-type facility and subsequently shipped and/or stored for later use.
- the coating can be applied to the medical device just prior to implantation in the patient.
- the process utilized to prepare the medical device will vary according to the particular embodiment desired, hi the case of the coating being applied in a manufacturing-type facility, the medical device is provided with the coating and subsequently sterilized in accordance with any of the methods provided herein, and/or any equivalents.
- the medical device is then packaged in a sterile environment and shipped or stored for later use. When use of the medical device is desired, the medical device is removed from the packaging and implanted in accordance with its specific design.
- the medical device can be prepared in advance.
- the medical device for example, can be sterilized and packaged in a sterile environment for later use.
- the medical device is removed from the packaging, and the coating substance is applied to result in the coating resident on the medical device.
- the present invention provides methods and devices for applying a coating to medical devices such as a stent.
- the methods and devices of the present invention provide a means for applying a coating that provides improved uniformity and coverage in a repeatable and controlled manner.
- the methods and devices also provide increased consistency in coating from device to device. This in turn allows for greater control of dosage of the bio-absorbable carrier and therapeutic agent.
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61374504P | 2004-09-28 | 2004-09-28 | |
US60/613,745 | 2004-09-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006037049A2 true WO2006037049A2 (en) | 2006-04-06 |
WO2006037049A3 WO2006037049A3 (en) | 2006-08-31 |
Family
ID=36119235
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/034610 WO2006036967A1 (en) | 2004-09-28 | 2005-09-28 | Solubilizing a drug for use in a coating |
PCT/US2005/034836 WO2006037049A2 (en) | 2004-09-28 | 2005-09-28 | Application of a coating on a medical device |
PCT/US2005/034679 WO2006036982A2 (en) | 2004-09-28 | 2005-09-28 | Drug delivery coating for use with a stent |
PCT/US2005/034681 WO2006036983A2 (en) | 2004-09-28 | 2005-09-28 | Pre-dried drug delivery coating for use with a stent |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/034610 WO2006036967A1 (en) | 2004-09-28 | 2005-09-28 | Solubilizing a drug for use in a coating |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/034679 WO2006036982A2 (en) | 2004-09-28 | 2005-09-28 | Drug delivery coating for use with a stent |
PCT/US2005/034681 WO2006036983A2 (en) | 2004-09-28 | 2005-09-28 | Pre-dried drug delivery coating for use with a stent |
Country Status (3)
Country | Link |
---|---|
US (7) | US8001922B2 (en) |
EP (1) | EP1804717A4 (en) |
WO (4) | WO2006036967A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9126025B2 (en) | 2008-05-01 | 2015-09-08 | Bayer Intellectual Property Gmbh | Method of coating a folded catheter balloon |
Families Citing this family (142)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6306166B1 (en) * | 1997-08-13 | 2001-10-23 | Scimed Life Systems, Inc. | Loading and release of water-insoluble drugs |
US8021331B2 (en) * | 2003-09-15 | 2011-09-20 | Atrium Medical Corporation | Method of coating a folded medical device |
US7349971B2 (en) * | 2004-02-05 | 2008-03-25 | Scenera Technologies, Llc | System for transmitting data utilizing multiple communication applications simultaneously in response to user request without specifying recipient's communication information |
US20060058737A1 (en) * | 2004-09-16 | 2006-03-16 | Herweck Steve A | Catheter treatment stylet |
US8367099B2 (en) | 2004-09-28 | 2013-02-05 | Atrium Medical Corporation | Perforated fatty acid films |
US20090011116A1 (en) * | 2004-09-28 | 2009-01-08 | Atrium Medical Corporation | Reducing template with coating receptacle containing a medical device to be coated |
WO2006036967A1 (en) | 2004-09-28 | 2006-04-06 | Atrium Medical Corporation | Solubilizing a drug for use in a coating |
US8312836B2 (en) | 2004-09-28 | 2012-11-20 | Atrium Medical Corporation | Method and apparatus for application of a fresh coating on a medical device |
US9801982B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Implantable barrier device |
US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US8962023B2 (en) * | 2004-09-28 | 2015-02-24 | Atrium Medical Corporation | UV cured gel and method of making |
US20060222627A1 (en) * | 2005-03-30 | 2006-10-05 | Andrew Carter | Optimizing pharmacodynamics of therapeutic agents for treating vascular tissue |
WO2006119018A2 (en) * | 2005-04-29 | 2006-11-09 | Atrium Medical Corporation | Drug delivery coating for use with a medical device and methods of treating vascular injury |
US20090062909A1 (en) | 2005-07-15 | 2009-03-05 | Micell Technologies, Inc. | Stent with polymer coating containing amorphous rapamycin |
CA2615452C (en) | 2005-07-15 | 2015-03-31 | Micell Technologies, Inc. | Polymer coatings containing drug powder of controlled morphology |
US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
US8574627B2 (en) | 2006-11-06 | 2013-11-05 | Atrium Medical Corporation | Coated surgical mesh |
US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
EP1933991A4 (en) * | 2005-10-15 | 2012-05-02 | Atrium Medical Corp | Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings |
US8784860B2 (en) * | 2005-10-27 | 2014-07-22 | Cordis Corporation | Local administration of a combination of rapamycin and cilostazol for the treatment of vascular disease |
CA2996768C (en) | 2006-04-26 | 2020-12-08 | Micell Technologies, Inc. | Coatings containing multiple drugs |
US20070260300A1 (en) * | 2006-05-04 | 2007-11-08 | Daniel Gregorich | Intraluminal medical device having a curable coating |
WO2007131802A1 (en) * | 2006-05-17 | 2007-11-22 | Ziscoat Nv | Fatty acid triglycerides for making biocompatible coatings |
EP2020956A2 (en) | 2006-05-26 | 2009-02-11 | Nanyang Technological University | Implantable article, method of forming same and method for reducing thrombogenicity |
US20070292305A1 (en) * | 2006-06-09 | 2007-12-20 | Sinead Dempsey | Sterilization of medical devices |
KR20090045916A (en) * | 2006-07-03 | 2009-05-08 | 헤모텍 아게 | Manufacture, method and use of drug-eluting medical devices for permanently keeping blood vessels open |
US9814557B2 (en) | 2006-10-10 | 2017-11-14 | Boston Scientific Scimed, Inc. | Stent protector design |
US9492596B2 (en) * | 2006-11-06 | 2016-11-15 | Atrium Medical Corporation | Barrier layer with underlying medical device and one or more reinforcing support structures |
US8414526B2 (en) * | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8430055B2 (en) * | 2008-08-29 | 2013-04-30 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
US20080175887A1 (en) * | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
US8414525B2 (en) * | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US20080181928A1 (en) * | 2006-12-22 | 2008-07-31 | Miv Therapeutics, Inc. | Coatings for implantable medical devices for liposome delivery |
CA2679712C (en) | 2007-01-08 | 2016-11-15 | Micell Technologies, Inc. | Stents having biodegradable layers |
US11426494B2 (en) | 2007-01-08 | 2022-08-30 | MT Acquisition Holdings LLC | Stents having biodegradable layers |
RU2447901C2 (en) * | 2007-01-21 | 2012-04-20 | Хемотек Аг | Medical device for treating lumen obturations and preventing threatening recurrent obturations |
US7938286B2 (en) * | 2007-02-13 | 2011-05-10 | Gateway Plastics, Inc. | Container system |
US20080207756A1 (en) * | 2007-02-27 | 2008-08-28 | Atrium Medical Corporation | Bio-absorbable oil suspension |
US8119151B2 (en) * | 2007-04-20 | 2012-02-21 | Boston Scientific Scimed, Inc. | Spread coating a medical device |
US7959857B2 (en) * | 2007-06-01 | 2011-06-14 | Abbott Cardiovascular Systems Inc. | Radiation sterilization of medical devices |
JP2008305262A (en) * | 2007-06-08 | 2008-12-18 | Konica Minolta Business Technologies Inc | Printer introduction method in server and thin client environment |
US8133553B2 (en) | 2007-06-18 | 2012-03-13 | Zimmer, Inc. | Process for forming a ceramic layer |
US8309521B2 (en) | 2007-06-19 | 2012-11-13 | Zimmer, Inc. | Spacer with a coating thereon for use with an implant device |
US9192697B2 (en) | 2007-07-03 | 2015-11-24 | Hemoteq Ag | Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis |
DE102007032686A1 (en) * | 2007-07-13 | 2009-01-15 | Biotronik Vi Patent Ag | Stent with a coating |
WO2009018325A1 (en) * | 2007-07-30 | 2009-02-05 | Atrium Medical Corporation | Method and apparatus for application of a fresh coating on a medical device |
WO2009041691A1 (en) * | 2007-09-28 | 2009-04-02 | Terumo Kabushiki Kaisha | In-vivo indwelling matter |
US8608049B2 (en) | 2007-10-10 | 2013-12-17 | Zimmer, Inc. | Method for bonding a tantalum structure to a cobalt-alloy substrate |
US20090099651A1 (en) * | 2007-10-10 | 2009-04-16 | Miv Therapeutics, Inc. | Lipid coatings for implantable medical devices |
US20090099531A1 (en) * | 2007-10-15 | 2009-04-16 | Griesbach Iii Henry Louis | Packaging for selectivity lubricating part of a medical device |
EP2220208A4 (en) * | 2007-11-23 | 2010-12-29 | Rappaport Family Inst For Res | Use of haptoglobin genotyping in diagnosis and treatment of cardiovascular disease |
EP2271294B1 (en) | 2008-04-17 | 2018-03-28 | Micell Technologies, Inc. | Stents having bioabsorbable layers |
DE102008020415A1 (en) | 2008-04-24 | 2009-10-29 | Biotronik Vi Patent Ag | Biodegradable metallic stents with wax layer |
GR1006552B (en) * | 2008-04-24 | 2009-10-02 | Νικολαος Χρηστου Δημοφιλος | Endoprostatic srping (stent) impregnated with rapamycin/sirolimus and shiga toxin acting against cancer of prostate and benign hyperplasias of the urologic tract |
SI2310059T1 (en) | 2008-05-29 | 2017-04-26 | Numat Biomedical S.L. | Pufa covered implants |
DE102008026207B4 (en) * | 2008-05-30 | 2015-01-15 | Manouchehr Abdolali | Coating agent for coating a surface of a medical implant |
US10898620B2 (en) | 2008-06-20 | 2021-01-26 | Razmodics Llc | Composite stent having multi-axial flexibility and method of manufacture thereof |
US8206636B2 (en) | 2008-06-20 | 2012-06-26 | Amaranth Medical Pte. | Stent fabrication via tubular casting processes |
US8206635B2 (en) | 2008-06-20 | 2012-06-26 | Amaranth Medical Pte. | Stent fabrication via tubular casting processes |
US20100135949A1 (en) * | 2008-12-01 | 2010-06-03 | Becton, Dickinson And Company | Antimicrobial compositions |
EP2381963A4 (en) * | 2009-01-21 | 2014-07-02 | Meril Life Sciences Private Ltd | A medical device loaded with formulations for targeted delivery of biologically active material/s and method of manufacture thereof |
CN102481195B (en) | 2009-04-01 | 2015-03-25 | 米歇尔技术公司 | Drug delivery medical device |
US8821455B2 (en) | 2009-07-09 | 2014-09-02 | Becton, Dickinson And Company | Antimicrobial coating for dermally invasive devices |
EP3064230B1 (en) * | 2009-07-10 | 2019-04-10 | Boston Scientific Scimed, Inc. | Use of nanocrystals for a drug delivery balloon |
EP2453834A4 (en) | 2009-07-16 | 2014-04-16 | Micell Technologies Inc | Drug delivery medical device |
EP2453938B1 (en) * | 2009-07-17 | 2015-08-19 | Boston Scientific Scimed, Inc. | Nucleation of drug delivery balloons to provide improved crystal size and density |
US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
US20110045050A1 (en) * | 2009-08-24 | 2011-02-24 | Atrium Medical Corporation | Nanoemulsion formulations for direct delivery |
EP2475309A4 (en) | 2009-09-08 | 2015-07-29 | Atrium Medical Corp | Hernia patch |
US20110160645A1 (en) * | 2009-12-31 | 2011-06-30 | Boston Scientific Scimed, Inc. | Cryo Activated Drug Delivery and Cutting Balloons |
US11369498B2 (en) | 2010-02-02 | 2022-06-28 | MT Acquisition Holdings LLC | Stent and stent delivery system with improved deliverability |
US8758800B2 (en) | 2010-03-24 | 2014-06-24 | Covidien Lp | Therapeutic implant |
US8758799B2 (en) | 2010-03-24 | 2014-06-24 | Covidien Lp | Therapeutic implant |
US8758798B2 (en) | 2010-03-24 | 2014-06-24 | Covidien Lp | Therapeutic implant |
WO2011133655A1 (en) | 2010-04-22 | 2011-10-27 | Micell Technologies, Inc. | Stents and other devices having extracellular matrix coating |
DE102010022588A1 (en) * | 2010-05-27 | 2011-12-01 | Hemoteq Ag | Balloon catheter with a particle-free drug-releasing coating |
WO2011147409A2 (en) * | 2010-05-27 | 2011-12-01 | Hemoteq Ag | Coating of endoprostheses with a coating consisting of a tight mesh of polymer fibres |
US9211175B2 (en) | 2010-07-08 | 2015-12-15 | Covidien Lp | Self-detachable medical devices |
CA2805631C (en) | 2010-07-16 | 2018-07-31 | Micell Technologies, Inc. | Drug delivery medical device |
WO2012009707A2 (en) | 2010-07-16 | 2012-01-19 | Atrium Medical Corporation | Composition and methods for altering the rate of hydrolysis of cured oil-based materials |
FR2962646B1 (en) | 2010-07-16 | 2012-06-22 | Sofradim Production | PROSTHETIC WITH RADIO OPAQUE ELEMENT |
EP2611476B1 (en) | 2010-09-02 | 2016-08-10 | Boston Scientific Scimed, Inc. | Coating process for drug delivery balloons using heat-induced rewrap memory |
US9572907B2 (en) | 2010-10-01 | 2017-02-21 | Covidien Lp | Implantable polymeric films |
US8632839B2 (en) | 2010-10-19 | 2014-01-21 | Covidien Lp | Methods of forming self-supporting films for delivery of therapeutic agents |
US9861590B2 (en) | 2010-10-19 | 2018-01-09 | Covidien Lp | Self-supporting films for delivery of therapeutic agents |
US8920867B2 (en) | 2010-10-19 | 2014-12-30 | Covidien Lp | Methods of forming self-supporting films for delivery of therapeutic agents |
US9144634B2 (en) | 2011-01-14 | 2015-09-29 | Covidien Lp | Medical device with intrapore films |
US8986608B2 (en) | 2011-05-17 | 2015-03-24 | Abbott Cardiovascular Systems Inc. | Method for radiation sterilization of medical devices |
FR2977790B1 (en) | 2011-07-13 | 2013-07-19 | Sofradim Production | PROSTHETIC FOR UMBILIC HERNIA |
US8579924B2 (en) | 2011-07-26 | 2013-11-12 | Covidien Lp | Implantable devices including a mesh and a pivotable film |
US8669360B2 (en) | 2011-08-05 | 2014-03-11 | Boston Scientific Scimed, Inc. | Methods of converting amorphous drug substance into crystalline form |
US9782957B2 (en) | 2011-08-24 | 2017-10-10 | Covidien Lp | Medical device films |
WO2013028208A1 (en) | 2011-08-25 | 2013-02-28 | Boston Scientific Scimed, Inc. | Medical device with crystalline drug coating |
US10188772B2 (en) | 2011-10-18 | 2019-01-29 | Micell Technologies, Inc. | Drug delivery medical device |
US8932621B2 (en) | 2011-10-25 | 2015-01-13 | Covidien Lp | Implantable film/mesh composite |
US9005308B2 (en) | 2011-10-25 | 2015-04-14 | Covidien Lp | Implantable film/mesh composite for passage of tissue therebetween |
US9179994B2 (en) | 2011-10-25 | 2015-11-10 | Covidien Lp | Implantable film/mesh composite |
US20150134047A1 (en) * | 2011-11-07 | 2015-05-14 | Micell Technologies, Inc. | Safe drug eluting stent with absorbable coating |
IN2014DN06125A (en) | 2012-01-06 | 2015-08-14 | Omthera Pharmaceuticals Inc | |
US10206769B2 (en) | 2012-03-30 | 2019-02-19 | Covidien Lp | Implantable devices including a film providing folding characteristics |
JP6173437B2 (en) | 2012-05-07 | 2017-08-02 | オムセラ・ファーマシューティカルズ・インコーポレイテッド | Statins and omega-3 fatty acid compositions |
US9352119B2 (en) | 2012-05-15 | 2016-05-31 | Becton, Dickinson And Company | Blood control IV catheter with antimicrobial properties |
US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
FR2992662B1 (en) | 2012-06-28 | 2014-08-08 | Sofradim Production | KNIT WITH PICOTS |
FR2992547B1 (en) | 2012-06-29 | 2015-04-24 | Sofradim Production | PROSTHETIC FOR HERNIA |
US9579486B2 (en) | 2012-08-22 | 2017-02-28 | Becton, Dickinson And Company | Blood control IV catheter with antimicrobial properties |
WO2014066085A1 (en) | 2012-10-26 | 2014-05-01 | Lixiao Wang | Drug coated balloon catheters for nonvascular strictures |
US11504450B2 (en) | 2012-10-26 | 2022-11-22 | Urotronic, Inc. | Drug-coated balloon catheters for body lumens |
US10850076B2 (en) | 2012-10-26 | 2020-12-01 | Urotronic, Inc. | Balloon catheters for body lumens |
WO2016172343A1 (en) | 2015-04-24 | 2016-10-27 | Urotronic, Inc. | Drug coated balloon catheters for nonvascular strictures |
US10898700B2 (en) | 2012-10-26 | 2021-01-26 | Urotronic, Inc. | Balloon catheters for body lumens |
US11938287B2 (en) | 2012-10-26 | 2024-03-26 | Urotronic, Inc. | Drug-coated balloon catheters for body lumens |
US10806830B2 (en) | 2012-10-26 | 2020-10-20 | Urotronic, Inc. | Drug-coated balloon catheters for body lumens |
US10881839B2 (en) | 2012-10-26 | 2021-01-05 | Urotronic, Inc. | Drug-coated balloon catheters for body lumens |
US9750928B2 (en) | 2013-02-13 | 2017-09-05 | Becton, Dickinson And Company | Blood control IV catheter with stationary septum activator |
US9695323B2 (en) | 2013-02-13 | 2017-07-04 | Becton, Dickinson And Company | UV curable solventless antimicrobial compositions |
WO2014127278A2 (en) * | 2013-02-18 | 2014-08-21 | Elutin, Inc. | Site specific drug delivery wraps, systems and methods of use thereof |
US9750927B2 (en) | 2013-03-11 | 2017-09-05 | Becton, Dickinson And Company | Blood control catheter with antimicrobial needle lube |
US9327095B2 (en) | 2013-03-11 | 2016-05-03 | Becton, Dickinson And Company | Blood control catheter with antimicrobial needle lube |
KR102079613B1 (en) | 2013-05-15 | 2020-02-20 | 미셀 테크놀로지즈, 인코포레이티드 | Bioabsorbable biomedical implants |
DE102013214636A1 (en) * | 2013-07-26 | 2015-01-29 | Heraeus Medical Gmbh | Bioresorbable material composites containing magnesium and magnesium alloys as well as implants from these composites |
US11839698B2 (en) | 2014-03-13 | 2023-12-12 | W. L. Gore & Associates, Inc. | Drug composition and coating |
US9789279B2 (en) | 2014-04-23 | 2017-10-17 | Becton, Dickinson And Company | Antimicrobial obturator for use with vascular access devices |
US9675793B2 (en) | 2014-04-23 | 2017-06-13 | Becton, Dickinson And Company | Catheter tubing with extraluminal antimicrobial coating |
US10376686B2 (en) | 2014-04-23 | 2019-08-13 | Becton, Dickinson And Company | Antimicrobial caps for medical connectors |
WO2016004321A1 (en) * | 2014-07-03 | 2016-01-07 | Board Of Regents, The University Of Texas System | Compounds for treating biofilm infection |
US10232088B2 (en) | 2014-07-08 | 2019-03-19 | Becton, Dickinson And Company | Antimicrobial coating forming kink resistant feature on a vascular access device |
US11904072B2 (en) | 2015-04-24 | 2024-02-20 | Urotronic, Inc. | Drug coated balloon catheters for nonvascular strictures |
US10561766B2 (en) | 2015-09-15 | 2020-02-18 | W. L. Gore & Associates, Inc. | Drug composition and coating |
US10493244B2 (en) | 2015-10-28 | 2019-12-03 | Becton, Dickinson And Company | Extension tubing strain relief |
US20170340899A1 (en) * | 2016-05-25 | 2017-11-30 | Boston Scientific Scimed, Inc. | Radioactive stent |
CN109477044B (en) | 2016-07-19 | 2021-10-08 | 艺康美国股份有限公司 | Method and cleaning solution for removing chewing gum and other sticky food |
ES2960921T3 (en) | 2017-03-27 | 2024-03-07 | Regeneron Pharma | Sterilization procedure |
WO2020219894A1 (en) * | 2019-04-25 | 2020-10-29 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Implantable device coated by a self-assembled monolayer and therapeutic agent |
CN113648457A (en) * | 2021-07-27 | 2021-11-16 | 南方科技大学 | Medical titanium implant, preparation method thereof and application of medical titanium implant |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3967728A (en) * | 1973-03-02 | 1976-07-06 | International Paper Company | Catheter package |
US5403283A (en) * | 1993-10-28 | 1995-04-04 | Luther Medical Products, Inc. | Percutaneous port catheter assembly and method of use |
US6152944A (en) * | 1997-03-05 | 2000-11-28 | Scimed Life Systems, Inc. | Catheter with removable balloon protector and stent delivery system with removable stent protector |
US20020012741A1 (en) * | 2000-07-28 | 2002-01-31 | Jochen Heinz | Process and apparatus for applying a thermally attached lubricating coating on an interior wall of a cylindrical container for medicinal purposes |
US20020116045A1 (en) * | 2001-02-22 | 2002-08-22 | Eidenschink Tracee E.J. | Crimpable balloon/stent protector |
US6565659B1 (en) * | 2001-06-28 | 2003-05-20 | Advanced Cardiovascular Systems, Inc. | Stent mounting assembly and a method of using the same to coat a stent |
Family Cites Families (325)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2403458A (en) | 1946-07-09 | Solvent extraction of drying oils | ||
US2735814A (en) | 1956-02-21 | Die forging compound | ||
US1948959A (en) | 1934-02-27 | Coating material | ||
US2368306A (en) | 1941-05-02 | 1945-01-30 | Stackpole Carbon Co | Method of treating electrodes |
US2986540A (en) | 1958-08-01 | 1961-05-30 | Stamford Rubber Supply Company | Organic plastic materials made from vulcanized oils and their preparation |
US3464413A (en) | 1967-05-26 | 1969-09-02 | United Merchants & Mfg | Medical bandages |
US3556294A (en) * | 1968-11-25 | 1971-01-19 | Bard Inc C R | Catheter package with self-contained lubricant |
US3567820A (en) | 1969-04-09 | 1971-03-02 | George S Sperti | Compositions and treatment for the alleviation of diaper rash |
JPS4826844B1 (en) | 1970-11-17 | 1973-08-16 | ||
DE2828623C2 (en) | 1978-06-29 | 1983-11-17 | Kernforschungsanlage Jülich GmbH, 5170 Jülich | C 1 6 -to C 1 8 fatty acids, a process for their preparation and their use, labeled with radioactive fluorine |
DE2842938A1 (en) | 1978-10-02 | 1980-04-17 | Roehm Gmbh | METHOD FOR POLYMERIZING BY UV LIGHT |
US4447418A (en) | 1981-03-06 | 1984-05-08 | Maddoux Lilla A | Animal medicine |
US4557925A (en) | 1982-07-08 | 1985-12-10 | Ab Ferrosan | Membrane-coated sustained-release tablets and method |
SE8206744D0 (en) * | 1982-11-26 | 1982-11-26 | Fluidcarbon International Ab | PREPARATION FOR CONTROLLED RELEASE OF SUBSTANCES |
SE456346B (en) | 1984-07-23 | 1988-09-26 | Pharmacia Ab | GEL TO PREVENT ADHESION BETWEEN BODY TISSUE AND SET FOR ITS PREPARATION |
US5176956A (en) | 1984-09-26 | 1993-01-05 | Medtronic, Inc. | Biomedical apparatus having fatty acid dimer derived skin compatible adhesive composition thereon |
US5411951A (en) | 1984-10-04 | 1995-05-02 | Monsanto Company | Prolonged release of biologically active somatotropin |
HU193951B (en) | 1985-03-11 | 1987-12-28 | Richter Gedeon Vegyeszet | Process for producing new sulfur-containing 5-substituted benzimidazol derivatives and pharmaceutical compositions containing them |
US4895724A (en) * | 1985-06-07 | 1990-01-23 | Pfizer Inc. | Chitosan compositions for controlled and prolonged release of macromolecules |
US4664114A (en) | 1985-08-12 | 1987-05-12 | Kamran Ghodsian | Dilator for cervical canal |
US4883667A (en) | 1985-08-16 | 1989-11-28 | Alza Corporation | Process for forming dispensing device |
JPS6274364A (en) | 1985-09-27 | 1987-04-06 | 株式会社 ニツシヨ− | Medical applicance |
US4847301A (en) | 1985-11-13 | 1989-07-11 | Pennwalt Corporation | Methods of use of α-(aminoalkyl)-arylacetic acid derivatives |
IN166447B (en) | 1985-11-27 | 1990-05-12 | Ethicon Inc | |
US5061281A (en) | 1985-12-17 | 1991-10-29 | Allied-Signal Inc. | Bioresorbable polymers and implantation devices thereof |
DE3634016A1 (en) | 1986-04-17 | 1987-10-29 | Lohmann Gmbh & Co Kg | AREA-BASED THERAPEUTIC SYSTEM, METHOD FOR THE PRODUCTION THEREOF AND ITS USE |
DE3644984A1 (en) * | 1986-07-01 | 1988-07-07 | Eberhardt Schlueter | Cartridge or ampoule for an injection device and automatic injection device |
US5371109A (en) | 1986-07-01 | 1994-12-06 | Drilletten Ab | Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase |
US4911707A (en) | 1987-02-13 | 1990-03-27 | Ciba-Geigy Corporation | Monolithic user-activated transdermal therapeutic system |
IL81975A0 (en) | 1987-03-24 | 1987-10-20 | Haifa Chemicals Ltd | Method for the manufacture of slow-release fertilizers |
US6387379B1 (en) * | 1987-04-10 | 2002-05-14 | University Of Florida | Biofunctional surface modified ocular implants, surgical instruments, medical devices, prostheses, contact lenses and the like |
US4894231A (en) | 1987-07-28 | 1990-01-16 | Biomeasure, Inc. | Therapeutic agent delivery system |
US4947840A (en) | 1987-08-21 | 1990-08-14 | Massachusetts Institute Of Technology | Biodegradable templates for the regeneration of tissues |
US4846844A (en) * | 1987-08-31 | 1989-07-11 | Eli Lilly And Company | Antimicrobial coated implants |
US5017229A (en) | 1990-06-25 | 1991-05-21 | Genzyme Corporation | Water insoluble derivatives of hyaluronic acid |
DE3734147C2 (en) * | 1987-10-09 | 1998-10-29 | Braun Melsungen Ag | Isotonic omega-3 fatty acid-containing fat emulsion and its use |
US5254105A (en) | 1988-05-26 | 1993-10-19 | Haaga John R | Sheath for wound closure caused by a medical tubular device |
US4941308A (en) | 1988-07-25 | 1990-07-17 | Abbott Laboratories | Method of packaging for a sterilizable calibratable medical device |
DE68922497T2 (en) | 1988-08-24 | 1995-09-14 | Marvin J Slepian | ENDOLUMINAL SEAL WITH BISDEGRADABLE POLYMERS. |
US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
DE3903056A1 (en) | 1989-02-02 | 1990-08-09 | Braun Melsungen Ag | FAT EMULSION FOR INTRAPERITONEAL APPLICATION, ITS PRODUCTION AND APPLICATION |
US6146358A (en) * | 1989-03-14 | 2000-11-14 | Cordis Corporation | Method and apparatus for delivery of therapeutic agent |
US5171148A (en) | 1989-06-30 | 1992-12-15 | Ethicon, Inc. | Dental inserts for treatment of periodontal disease |
FR2653338B1 (en) * | 1989-10-23 | 1994-06-10 | Dow Corning Sa | FORMULATION FOR SUSTAINED RELEASE DRUGS AND THE USE THEREOF. |
US5843089A (en) * | 1990-12-28 | 1998-12-01 | Boston Scientific Corporation | Stent lining |
US5179174A (en) | 1990-04-23 | 1993-01-12 | C. R. Bard, Inc. | Flexible lubricious organic coatings |
US5202310A (en) | 1990-06-06 | 1993-04-13 | Levy Gary A | Cyclosporine metabolites |
GB9018144D0 (en) | 1990-08-17 | 1990-10-03 | Unilever Plc | Polymerisation process |
DE4133694C2 (en) | 1991-10-11 | 1993-10-07 | Fresenius Ag | Use of an emulsion with polyunsaturated fatty acids for i.v. administration for the treatment of skin diseases |
US5147374A (en) | 1991-12-05 | 1992-09-15 | Alfredo Fernandez | Prosthetic mesh patch for hernia repair |
US5683448A (en) | 1992-02-21 | 1997-11-04 | Boston Scientific Technology, Inc. | Intraluminal stent and graft |
SE9200541D0 (en) | 1992-02-24 | 1992-02-24 | Kabi Pharmacia Ab | NEW USEE OF OMEGA-3-FATTY ACIDS |
CA2117588C (en) | 1992-02-28 | 1998-08-25 | Jeffrey A. Hubbell | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
WO1993017635A1 (en) | 1992-03-04 | 1993-09-16 | C.R. Bard, Inc. | Composite prosthesis and method for limiting the incidence of postoperative adhesions |
US5766246A (en) | 1992-05-20 | 1998-06-16 | C. R. Bard, Inc. | Implantable prosthesis and method and apparatus for loading and delivering an implantable prothesis |
DE4222380A1 (en) * | 1992-07-08 | 1994-01-13 | Ernst Peter Prof Dr M Strecker | Endoprosthesis implantable percutaneously in a patient's body |
US5879359A (en) | 1992-08-03 | 1999-03-09 | Fidia S.P.A. | Biodegradable guide channels comprised of esters of hyaluronic acid for use in tissue repair as surgical aids |
US5753343A (en) * | 1992-08-04 | 1998-05-19 | Minnesota Mining And Manufacturing Company | Corrugated nonwoven webs of polymeric microfiber |
DE4236912A1 (en) * | 1992-10-31 | 1994-05-05 | Huels Chemische Werke Ag | Crosslinked castor oil derivatives |
DE4238994A1 (en) | 1992-11-19 | 1994-05-26 | Basf Ag | Aniline as a marking agent for mineral oils |
CA2114290C (en) | 1993-01-27 | 2006-01-10 | Nagabushanam Totakura | Post-surgical anti-adhesion device |
US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5356432B1 (en) | 1993-02-05 | 1997-02-04 | Bard Inc C R | Implantable mesh prosthesis and method for repairing muscle or tissue wall defects |
US5368602A (en) | 1993-02-11 | 1994-11-29 | De La Torre; Roger A. | Surgical mesh with semi-rigid border members |
US5433996A (en) | 1993-02-18 | 1995-07-18 | W. L. Gore & Associates, Inc. | Laminated patch tissue repair sheet material |
GB2280850B (en) | 1993-07-28 | 1997-07-30 | Johnson & Johnson Medical | Absorbable composite materials for use in the treatment of periodontal disease |
US6015844A (en) | 1993-03-22 | 2000-01-18 | Johnson & Johnson Medical, Inc. | Composite surgical material |
US5464650A (en) | 1993-04-26 | 1995-11-07 | Medtronic, Inc. | Intravascular stent and method |
US5380328A (en) | 1993-08-09 | 1995-01-10 | Timesh, Inc. | Composite perforated implant structures |
EP0713364A4 (en) | 1993-08-13 | 1996-12-27 | Shalaby W Shalaby | Microporous polymeric foams and microtextured surfaces |
FR2710161B1 (en) | 1993-09-13 | 1995-11-24 | Suisse Electronique Microtech | Miniature array of light shutters. |
US5411988A (en) | 1993-10-27 | 1995-05-02 | Bockow; Barry I. | Compositions and methods for inhibiting inflammation and adhesion formation |
US6228383B1 (en) | 1994-03-03 | 2001-05-08 | Gs Development Ab | Use of fatty acid esters as bioadhesive substances |
AU685262B2 (en) | 1994-03-30 | 1998-01-15 | Gs Development Ab | Use of fatty acid esters as bioadhesive substances |
US5760081A (en) | 1994-05-10 | 1998-06-02 | The General Hospital Corporation | Omega 3 fatty acids in the prevention of ventricular fibrillation |
US5547677A (en) | 1994-05-20 | 1996-08-20 | Novavax, Inc. | Antimicrobial oil-in-water emulsions |
US5549901A (en) | 1994-05-20 | 1996-08-27 | Novavax, Inc. | Antimicrobial oil-in-water emulsions |
US5629077A (en) | 1994-06-27 | 1997-05-13 | Advanced Cardiovascular Systems, Inc. | Biodegradable mesh and film stent |
US5716614A (en) * | 1994-08-05 | 1998-02-10 | Molecular/Structural Biotechnologies, Inc. | Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier |
US5931165A (en) | 1994-09-06 | 1999-08-03 | Fusion Medical Technologies, Inc. | Films having improved characteristics and methods for their preparation and use |
US5591230A (en) * | 1994-09-07 | 1997-01-07 | Global Therapeutics, Inc. | Radially expandable stent |
SE518619C2 (en) | 1994-12-09 | 2002-10-29 | Gs Dev Ab | Controlled release composition containing monocaproin |
US5509899A (en) | 1994-09-22 | 1996-04-23 | Boston Scientific Corp. | Medical device with lubricious coating |
US6176863B1 (en) | 1994-09-29 | 2001-01-23 | Bard Asdi Inc. | Hernia mesh patch with I-shaped filament |
US5637113A (en) | 1994-12-13 | 1997-06-10 | Advanced Cardiovascular Systems, Inc. | Polymer film for wrapping a stent structure |
US6262109B1 (en) * | 1995-12-22 | 2001-07-17 | Henkel Corporation | Methods of preventing and/or treating high serum levels of cholesterol and/or lipids |
US5629021A (en) | 1995-01-31 | 1997-05-13 | Novavax, Inc. | Micellar nanoparticles |
US5496832A (en) | 1995-03-09 | 1996-03-05 | American Home Products Corporation | Method of treating cardiac inflammatory disease |
US5580923A (en) | 1995-03-14 | 1996-12-03 | Collagen Corporation | Anti-adhesion films and compositions for medical use |
US6048725A (en) | 1995-03-17 | 2000-04-11 | Hisamitsu Pharmaceutical Co., Inc. | Recombinant human immunodeficiency virus producing cell lines |
US5900245A (en) | 1996-03-22 | 1999-05-04 | Focal, Inc. | Compliant tissue sealants |
US5837313A (en) * | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
MY118354A (en) | 1995-05-01 | 2004-10-30 | Scarista Ltd | 1,3-propane diol derivatives as bioactive compounds |
SE504582C2 (en) | 1995-07-06 | 1997-03-10 | Gs Dev Ab | Cyclosporin composition based on an L2 phase |
ES2244975T3 (en) | 1995-08-29 | 2005-12-16 | Fidia Advanced Biopolymers S.R.L. | BIOMATERIALS FOR THE PREVENTION OF POST-SURGICAL ADHERENCES, FORMED BY HIALURONIC ACID DERIVATIVES. |
GB9602638D0 (en) | 1995-09-07 | 1996-04-10 | Croda Int Plc | Triglyceride drying oil derivatives |
WO1997013528A1 (en) | 1995-10-12 | 1997-04-17 | Gs Development Ab | A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
US5714360A (en) | 1995-11-03 | 1998-02-03 | Bsi Corporation | Photoactivatable water soluble cross-linking agents containing an onium group |
US5612074A (en) * | 1995-12-21 | 1997-03-18 | Leach; Robin L. | Nutrient fortified food bar |
US6132765A (en) | 1996-04-12 | 2000-10-17 | Uroteq Inc. | Drug delivery via therapeutic hydrogels |
US5817343A (en) * | 1996-05-14 | 1998-10-06 | Alkermes, Inc. | Method for fabricating polymer-based controlled-release devices |
US6764509B2 (en) | 1996-09-06 | 2004-07-20 | Carbomedics Inc. | Prosthetic heart valve with surface modification |
AU4648697A (en) * | 1996-09-23 | 1998-04-14 | Chandrashekar Pathak | Methods and devices for preparing protein concentrates |
JP4151853B2 (en) | 1996-10-11 | 2008-09-17 | スカリスタ リミテッド | A therapeutic agent containing eicosapentaenoic acid and / or stearidonic acid |
EP0935425A4 (en) | 1996-10-25 | 2000-02-23 | Mccormick & Co Inc | Fat-coated encapsulation compositions and method for preparing the same |
US5843919A (en) | 1996-11-25 | 1998-12-01 | Burger; John A. | Composition and method for the treatment of arthritis |
SE511313C2 (en) | 1997-01-13 | 1999-09-06 | Gs Dev Ab | A controlled release composition comprising diacylglycerol fatty acid ester |
IL121320A (en) | 1997-02-23 | 2000-12-06 | Ibr Ltd | Extracts from cells or tissue of organisms which are capable of entering dormancy for inhibition of proliferation of target cells or tissue |
AU6959898A (en) | 1997-04-11 | 1998-11-11 | David J. Grainger | Compounds and therapies for the prevention of vascular and non-vascular pathol ogies |
US10028851B2 (en) | 1997-04-15 | 2018-07-24 | Advanced Cardiovascular Systems, Inc. | Coatings for controlling erosion of a substrate of an implantable medical device |
US6273913B1 (en) * | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
US6120539A (en) * | 1997-05-01 | 2000-09-19 | C. R. Bard Inc. | Prosthetic repair fabric |
US6630151B1 (en) | 1997-05-27 | 2003-10-07 | Baker Hughes Incorporated | Method of increasing viscosity of oil-based compositions and compositions resulting therefrom |
PT917561E (en) | 1997-05-29 | 2003-11-28 | Leuven K U Res & Dev | ELIMINATION OF COMPOUNDS OF FATTY ACIDS TRANS-INSATURATED BY ADSORCAO WITH ZEOLITES |
US5824082A (en) | 1997-07-14 | 1998-10-20 | Brown; Roderick B. | Patch for endoscopic repair of hernias |
KR100515184B1 (en) | 1997-08-15 | 2005-09-16 | 유니티카 가부시끼가이샤 | Mannose-containing feed and process for producing the same |
US5854382A (en) | 1997-08-18 | 1998-12-29 | Meadox Medicals, Inc. | Bioresorbable compositions for implantable prostheses |
US6884429B2 (en) | 1997-09-05 | 2005-04-26 | Isotechnika International Inc. | Medical devices incorporating deuterated rapamycin for controlled delivery thereof |
US6281175B1 (en) | 1997-09-23 | 2001-08-28 | Scimed Life Systems, Inc. | Medical emulsion for lubrication and delivery of drugs |
US6083950A (en) | 1997-11-13 | 2000-07-04 | Ranbaxy Laboratories Limited | 1-(4-arylpiperazin-1-yl)-ω-[n-(α,ω-dicarboximido)]-alka nes useful as uro-selective α1-adrenoceptor blockers |
ID26335A (en) | 1997-11-17 | 2000-12-14 | Lipogenic Inc | METHOD FOR PREVENTING RESTENOSIS USING TOKOTRIENOL |
CA2313024C (en) | 1997-12-10 | 2008-06-03 | Severson, Mary L. | Pharmaceutical compositions containing an omega-3 fatty acid oil |
US6187335B1 (en) | 1997-12-31 | 2001-02-13 | Orasomal Technologies, Inc. | Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom |
US20020002154A1 (en) | 1998-02-11 | 2002-01-03 | Pol-Henri Guivarc'h | Method and composition for treatment of inflammatory conditions |
US6326360B1 (en) * | 1998-03-11 | 2001-12-04 | Grelan Pharmaceuticals Co., Ltd. | Bubbling enteric coated preparations |
US6465525B1 (en) * | 1998-03-18 | 2002-10-15 | Surmodics, Inc. | Latent reactive blood compatible agents |
US6206916B1 (en) * | 1998-04-15 | 2001-03-27 | Joseph G. Furst | Coated intraluminal graft |
US20030040790A1 (en) | 1998-04-15 | 2003-02-27 | Furst Joseph G. | Stent coating |
US6056970A (en) * | 1998-05-07 | 2000-05-02 | Genzyme Corporation | Compositions comprising hemostatic compounds and bioabsorbable polymers |
US6010776A (en) * | 1998-05-19 | 2000-01-04 | 3M Innovative Properties Company | Microporous materials containing cross-linked oil |
US6197357B1 (en) | 1998-05-28 | 2001-03-06 | University Of Massachusetts | Refined vegetable oils and extracts thereof |
JP4439734B2 (en) | 1998-06-03 | 2010-03-24 | ブルー・メディカル・デバイシーズ・ベスローテン・フェンノートシャップ | Stent with diamond-like coating |
US6254634B1 (en) * | 1998-06-10 | 2001-07-03 | Surmodics, Inc. | Coating compositions |
DE19929184A1 (en) | 1998-06-26 | 1999-12-30 | Mclaughlin James A | Radio frequency plasma enhanced chemical vapor deposition of diamond like films onto medical devices such as catheter wires |
US6369039B1 (en) | 1998-06-30 | 2002-04-09 | Scimed Life Sytems, Inc. | High efficiency local drug delivery |
US6669735B1 (en) | 1998-07-31 | 2003-12-30 | Davol, Inc. | Prosthesis for surgical treatment of hernia |
JP4898991B2 (en) * | 1998-08-20 | 2012-03-21 | クック メディカル テクノロジーズ エルエルシー | Sheathed medical device |
US6093792A (en) | 1998-09-16 | 2000-07-25 | University Of Massachusetts | Bioresorbable copolymers |
JP4613275B2 (en) | 1998-11-02 | 2011-01-12 | エラン ファーマ インターナショナル,リミティド | Multiparticulate modified release composition |
US6211315B1 (en) * | 1998-11-12 | 2001-04-03 | Iowa State University Research Foundation, Inc. | Lewis acid-catalyzed polymerization of biological oils and resulting polymeric materials |
EP1140243B1 (en) | 1998-12-31 | 2003-04-09 | Angiotech Pharmaceuticals, Inc. | Stent grafts with bioactive coatings |
US6040330A (en) * | 1999-01-08 | 2000-03-21 | Bionumerik Pharmaceuticals, Inc. | Pharmaceutical formulations of taxanes |
US7238711B1 (en) | 1999-03-17 | 2007-07-03 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
KR100451527B1 (en) * | 1999-01-25 | 2004-10-08 | 에코신테틱스 인코포레이티드 | Biopolymer nanoparticles |
US7947015B2 (en) | 1999-01-25 | 2011-05-24 | Atrium Medical Corporation | Application of a therapeutic substance to a tissue location using an expandable medical device |
SE9900465D0 (en) * | 1999-02-12 | 1999-02-12 | Astra Ab | Storage package |
US6761903B2 (en) * | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
CA2363262C (en) | 1999-03-04 | 2010-09-28 | Tepha, Inc. | Bioabsorbable, biocompatible polymers for tissue engineering |
US6368658B1 (en) | 1999-04-19 | 2002-04-09 | Scimed Life Systems, Inc. | Coating medical devices using air suspension |
ATE355288T1 (en) * | 1999-05-14 | 2006-03-15 | Univ Australian | COMPOUNDS AND THERAPEUTIC METHODS |
US6610035B2 (en) | 1999-05-21 | 2003-08-26 | Scimed Life Systems, Inc. | Hydrophilic lubricity coating for medical devices comprising a hybrid top coat |
US6673843B2 (en) | 1999-06-30 | 2004-01-06 | Emory University | Curcumin and curcuminoid inhibition of angiogenesis |
WO2001006973A1 (en) | 1999-07-28 | 2001-02-01 | United States Surgical Corporation | Hyaluronic acid anti-adhesion barrier |
US6762203B2 (en) * | 1999-08-03 | 2004-07-13 | Kao Corporation | Oil composition |
US20030224071A1 (en) | 1999-08-20 | 2003-12-04 | Howard Murad | Pharmaceutical compositions and methods for managing connective tissue ailments |
US6503556B2 (en) * | 2000-12-28 | 2003-01-07 | Advanced Cardiovascular Systems, Inc. | Methods of forming a coating for a prosthesis |
US6497833B1 (en) | 1999-09-30 | 2002-12-24 | Amad Tayebi | Colored laminate and a method for coloring the surface of a membrane |
US6203551B1 (en) | 1999-10-04 | 2001-03-20 | Advanced Cardiovascular Systems, Inc. | Chamber for applying therapeutic substances to an implant device |
US6468354B2 (en) | 1999-10-05 | 2002-10-22 | Taiwan Semiconductor Manufacturing Co., Ltd | Semiconductor wafer support |
CN1390149A (en) | 1999-10-06 | 2003-01-08 | 宾夕法尼亚州研究基金会 | System and device for preventing restenosis in body vessels |
AU8023200A (en) | 1999-10-13 | 2001-04-23 | Biocardia, Inc. | Pulmonary vein stent and method for use |
JP2001120582A (en) | 1999-10-22 | 2001-05-08 | Gunze Ltd | Artificial cardiac valve and method of manufacturing the same |
US6828346B2 (en) | 1999-10-25 | 2004-12-07 | Supergen, Inc. | Methods for administration of paclitaxel |
US7066912B2 (en) * | 1999-12-17 | 2006-06-27 | Astra Tech Ab | Catheter wetting apparatus |
US6447835B1 (en) | 2000-02-15 | 2002-09-10 | Scimed Life Systems, Inc. | Method of coating polymeric tubes used in medical devices |
JP2004505886A (en) * | 2000-02-18 | 2004-02-26 | スィーヴィー セラピューティクス インコーポレイテッド | Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure |
EP1132058A1 (en) * | 2000-03-06 | 2001-09-12 | Advanced Laser Applications Holding S.A. | Intravascular prothesis |
US9314339B2 (en) | 2000-03-27 | 2016-04-19 | Formae, Inc. | Implants for replacing cartilage, with negatively-charged hydrogel surfaces and flexible matrix reinforcement |
SE520688C2 (en) | 2000-04-11 | 2003-08-12 | Bone Support Ab | An injectable bone mineral replacement material |
US6527801B1 (en) * | 2000-04-13 | 2003-03-04 | Advanced Cardiovascular Systems, Inc. | Biodegradable drug delivery material for stent |
US7875283B2 (en) * | 2000-04-13 | 2011-01-25 | Advanced Cardiovascular Systems, Inc. | Biodegradable polymers for use with implantable medical devices |
WO2001079315A1 (en) * | 2000-04-18 | 2001-10-25 | Clemson University | Polylactide/dextran graft co-polymers for biomaterial and tissue engineering applications |
US7419678B2 (en) | 2000-05-12 | 2008-09-02 | Cordis Corporation | Coated medical devices for the prevention and treatment of vascular disease |
US6776796B2 (en) * | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
US6670355B2 (en) * | 2000-06-16 | 2003-12-30 | Wyeth | Method of treating cardiovascular disease |
KR100734496B1 (en) | 2000-07-25 | 2007-07-03 | 미쓰이 가가쿠 가부시키가이샤 | Curable composition and uses thereof |
ATE392907T1 (en) | 2000-07-28 | 2008-05-15 | Anika Therapeutics Inc | BIOABSORBABLE COMPOSITE MATERIALS MADE OF DERIVATIZED HYALURONIC ACID |
US6451373B1 (en) | 2000-08-04 | 2002-09-17 | Advanced Cardiovascular Systems, Inc. | Method of forming a therapeutic coating onto a surface of an implantable prosthesis |
US6610068B1 (en) * | 2000-09-22 | 2003-08-26 | Scimed Life Systems, Inc. | Non-flush over-the-wire catheter devices |
US6421991B1 (en) * | 2000-09-26 | 2002-07-23 | Deere & Company | Doffer for a cotton cleaner |
US7261735B2 (en) | 2001-05-07 | 2007-08-28 | Cordis Corporation | Local drug delivery devices and methods for maintaining the drug coatings thereon |
ATA16992000A (en) | 2000-10-05 | 2001-12-15 | Michael Dr Koncar | METHOD FOR PRODUCING FATTY ACID ALKYL ESTERS |
US6485752B1 (en) | 2000-10-23 | 2002-11-26 | Otto Torbjorn Hansen | Composition and method for alleviating joint pain and stiffness |
US6794485B2 (en) | 2000-10-27 | 2004-09-21 | Poly-Med, Inc. | Amorphous polymeric polyaxial initiators and compliant crystalline copolymers therefrom |
US20020161168A1 (en) | 2000-10-27 | 2002-10-31 | Shalaby Shalaby W. | Amorphous polymeric polyaxial initiators and compliant crystalline copolymers therefrom |
JP4583756B2 (en) * | 2000-10-31 | 2010-11-17 | クック インコーポレイテッド | Medical instruments |
US7803149B2 (en) | 2002-07-12 | 2010-09-28 | Cook Incorporated | Coated medical device |
US20040018228A1 (en) | 2000-11-06 | 2004-01-29 | Afmedica, Inc. | Compositions and methods for reducing scar tissue formation |
US20050084514A1 (en) | 2000-11-06 | 2005-04-21 | Afmedica, Inc. | Combination drug therapy for reducing scar tissue formation |
US6534693B2 (en) | 2000-11-06 | 2003-03-18 | Afmedica, Inc. | Surgically implanted devices having reduced scar tissue formation |
US20040241211A9 (en) | 2000-11-06 | 2004-12-02 | Fischell Robert E. | Devices and methods for reducing scar tissue formation |
US7749539B2 (en) | 2000-11-30 | 2010-07-06 | Efrat Biopolymers Ltd. | Polymeric formulations for drug delivery |
US20040030377A1 (en) * | 2001-10-19 | 2004-02-12 | Alexander Dubson | Medicated polymer-coated stent assembly |
US20020084178A1 (en) | 2000-12-19 | 2002-07-04 | Nicast Corporation Ltd. | Method and apparatus for manufacturing polymer fiber shells via electrospinning |
US6852330B2 (en) | 2000-12-21 | 2005-02-08 | Depuy Mitek, Inc. | Reinforced foam implants with enhanced integrity for soft tissue repair and regeneration |
CA2365376C (en) | 2000-12-21 | 2006-03-28 | Ethicon, Inc. | Use of reinforced foam implants with enhanced integrity for soft tissue repair and regeneration |
US6599323B2 (en) | 2000-12-21 | 2003-07-29 | Ethicon, Inc. | Reinforced tissue implants and methods of manufacture and use |
US6471980B2 (en) * | 2000-12-22 | 2002-10-29 | Avantec Vascular Corporation | Intravascular delivery of mycophenolic acid |
US20020120333A1 (en) * | 2001-01-31 | 2002-08-29 | Keogh James R. | Method for coating medical device surfaces |
US6479683B1 (en) | 2001-03-06 | 2002-11-12 | Ag Processing Inc | Process for conjugating fatty acid esters |
US7771468B2 (en) | 2001-03-16 | 2010-08-10 | Angiotech Biocoatings Corp. | Medicated stent having multi-layer polymer coating |
EP2226018A1 (en) | 2001-03-26 | 2010-09-08 | Tyco Healthcare Group, LP | Oil coated sutures |
US7056339B2 (en) * | 2001-04-20 | 2006-06-06 | The Board Of Trustees Of The Leland Stanford Junior University | Drug delivery platform |
US20020161887A1 (en) * | 2001-04-27 | 2002-10-31 | Foster Michael S. | Method and system for performing security via de-registration in a communications network |
US7244853B2 (en) | 2001-05-09 | 2007-07-17 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
US6685956B2 (en) | 2001-05-16 | 2004-02-03 | The Research Foundation At State University Of New York | Biodegradable and/or bioabsorbable fibrous articles and methods for using the articles for medical applications |
US20030065292A1 (en) | 2001-06-08 | 2003-04-03 | Darouiche Rabih O. | Ozonated medical devices and methods of using ozone to prevent complications from indwelling medical devices |
US7201940B1 (en) | 2001-06-12 | 2007-04-10 | Advanced Cardiovascular Systems, Inc. | Method and apparatus for thermal spray processing of medical devices |
EP1402906A4 (en) | 2001-06-15 | 2007-04-25 | Gunze Kk | Synechia inhibitory material |
US6787179B2 (en) | 2001-06-29 | 2004-09-07 | Ethicon, Inc. | Sterilization of bioactive coatings |
US7030127B2 (en) | 2001-06-29 | 2006-04-18 | Ethicon, Inc. | Composition and medical devices utilizing bioabsorbable polymeric waxes |
US7034037B2 (en) | 2001-06-29 | 2006-04-25 | Ethicon, Inc. | Compositions and medical devices utilizing bioabsorbable polymeric waxes and rapamycin |
US6682771B2 (en) | 2001-07-02 | 2004-01-27 | Scimed Life Systems, Inc. | Coating dispensing system and method using a solenoid head for coating medical devices |
US7217431B2 (en) | 2001-07-06 | 2007-05-15 | Lifecycle Pharma A/S | Controlled agglomeration |
EP1273314A1 (en) | 2001-07-06 | 2003-01-08 | Terumo Kabushiki Kaisha | Stent |
US6444318B1 (en) * | 2001-07-17 | 2002-09-03 | Surmodics, Inc. | Self assembling monolayer compositions |
US6585997B2 (en) | 2001-08-16 | 2003-07-01 | Access Pharmaceuticals, Inc. | Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
US20040137066A1 (en) | 2001-11-26 | 2004-07-15 | Swaminathan Jayaraman | Rationally designed therapeutic intravascular implant coating |
US6641611B2 (en) * | 2001-11-26 | 2003-11-04 | Swaminathan Jayaraman | Therapeutic coating for an intravascular implant |
IN2014DN10834A (en) | 2001-09-17 | 2015-09-04 | Psivida Inc | |
US6753071B1 (en) | 2001-09-27 | 2004-06-22 | Advanced Cardiovascular Systems, Inc. | Rate-reducing membrane for release of an agent |
US20030065345A1 (en) * | 2001-09-28 | 2003-04-03 | Kevin Weadock | Anastomosis devices and methods for treating anastomotic sites |
US20030064965A1 (en) | 2001-10-02 | 2003-04-03 | Jacob Richter | Method of delivering drugs to a tissue using drug-coated medical devices |
US20030077310A1 (en) * | 2001-10-22 | 2003-04-24 | Chandrashekhar Pathak | Stent coatings containing HMG-CoA reductase inhibitors |
WO2003037397A2 (en) | 2001-10-31 | 2003-05-08 | Edwards Lifesciences Corporation | Drug eluting radially expandable tubular stented grafts |
ATE367172T1 (en) * | 2001-11-08 | 2007-08-15 | Atrium Medical Corp | INTRALUMINAL DEVICE HAVING A COATING CONTAINING A THERAPEUTIC AGENT |
WO2003041756A1 (en) | 2001-11-08 | 2003-05-22 | Dsb Invest Holding Sa | Endoluminal devices coated with latrunculin to prevent ingrowth of cells |
US6663880B1 (en) | 2001-11-30 | 2003-12-16 | Advanced Cardiovascular Systems, Inc. | Permeabilizing reagents to increase drug delivery and a method of local delivery |
ATE374628T1 (en) | 2001-11-30 | 2007-10-15 | Univ Laval | MILK PROTEIN BIOFILM AND USES THEREOF |
CA2470824A1 (en) | 2001-12-21 | 2003-08-28 | Cardiovasc, Inc. | Composite stent with polymeric covering and bioactive coating |
US6790213B2 (en) | 2002-01-07 | 2004-09-14 | C.R. Bard, Inc. | Implantable prosthesis |
US20030220297A1 (en) | 2002-02-01 | 2003-11-27 | Berstein David L. | Phosphorus-containing compounds and uses thereof |
US6887270B2 (en) | 2002-02-08 | 2005-05-03 | Boston Scientific Scimed, Inc. | Implantable or insertable medical device resistant to microbial growth and biofilm formation |
WO2003068505A1 (en) | 2002-02-13 | 2003-08-21 | Rf & Son, Inc. | Novel laminates for producing high strength porous sterilizable packaging |
US20030204168A1 (en) * | 2002-04-30 | 2003-10-30 | Gjalt Bosma | Coated vascular devices |
SE0201330D0 (en) * | 2002-04-30 | 2002-04-30 | Astra Tech Ab | Catheter assembly |
US7048962B2 (en) | 2002-05-02 | 2006-05-23 | Labcoat, Ltd. | Stent coating device |
US6645547B1 (en) * | 2002-05-02 | 2003-11-11 | Labcoat Ltd. | Stent coating device |
US20030207907A1 (en) | 2002-05-03 | 2003-11-06 | Iversen Patrick L. | Delivery of microparticle-conjugated drugs for inhibition of stenosis |
CN1655738A (en) | 2002-05-20 | 2005-08-17 | 奥勃斯医学技术股份有限公司 | Drug eluting implantable medical device |
EP1539032A2 (en) | 2002-07-02 | 2005-06-15 | Polycord, Inc. | Polymerized and modified rapamycins and their use in coating medical prostheses |
US6767405B2 (en) | 2002-07-10 | 2004-07-27 | Carmeda Ab | Apparatus and process for coating articles |
US7101381B2 (en) | 2002-08-02 | 2006-09-05 | C.R. Bard, Inc. | Implantable prosthesis |
EP1550477B1 (en) | 2002-08-23 | 2015-11-04 | National Cerebral and Cardiovascular Center | Stent and process for producing the same |
US7732535B2 (en) | 2002-09-05 | 2010-06-08 | Advanced Cardiovascular Systems, Inc. | Coating for controlled release of drugs from implantable medical devices |
US6875231B2 (en) | 2002-09-11 | 2005-04-05 | 3F Therapeutics, Inc. | Percutaneously deliverable heart valve |
EP1542739B1 (en) * | 2002-09-26 | 2008-12-10 | Angiotech International Ag | Perivascular wraps |
US6991096B2 (en) * | 2002-09-27 | 2006-01-31 | Medtronic Minimed, Inc. | Packaging system |
US20050095267A1 (en) | 2002-12-04 | 2005-05-05 | Todd Campbell | Nanoparticle-based controlled release polymer coatings for medical implants |
US6899729B1 (en) * | 2002-12-18 | 2005-05-31 | Advanced Cardiovascular Systems, Inc. | Stent for treating vulnerable plaque |
US7152611B2 (en) | 2002-12-30 | 2006-12-26 | International Tape Partners, Llc | Coated multifilament dental devices overcoated with imbedded particulate |
EP1596755B1 (en) | 2003-01-16 | 2016-10-12 | Massachusetts General Hospital | Methods for making oxidation resistant polymeric material |
US6919100B2 (en) * | 2003-01-22 | 2005-07-19 | Cordis Corporation | Method for coating medical devices |
US20040224003A1 (en) * | 2003-02-07 | 2004-11-11 | Schultz Robert K. | Drug formulations for coating medical devices |
US20040167572A1 (en) | 2003-02-20 | 2004-08-26 | Roth Noah M. | Coated medical devices |
EP1603485A4 (en) * | 2003-02-26 | 2011-03-30 | Medivas Llc | Bioactive stents and methods for use thereof |
US7077910B2 (en) | 2003-04-07 | 2006-07-18 | Surmodics, Inc. | Linear rail coating apparatus and method |
US7972616B2 (en) | 2003-04-17 | 2011-07-05 | Nanosys, Inc. | Medical device applications of nanostructured surfaces |
DE10318803B4 (en) | 2003-04-17 | 2005-07-28 | Translumina Gmbh | Device for applying active substances to surfaces of medical implants, in particular stents |
US20040230176A1 (en) * | 2003-04-23 | 2004-11-18 | Medtronic Vascular, Inc. | System for treating a vascular condition that inhibits restenosis at stent ends |
DE10323676A1 (en) | 2003-05-15 | 2004-12-02 | Aesculap Ag & Co. Kg | Implant with long-term antibiotic effect |
US8021418B2 (en) | 2003-06-19 | 2011-09-20 | Boston Scientific Scimed, Inc. | Sandwiched radiopaque marker on covered stent |
US6981944B2 (en) | 2003-07-07 | 2006-01-03 | Ethicon, Inc. | Implantable surgical mesh having a lubricious coating |
RU2360646C2 (en) | 2003-08-14 | 2009-07-10 | Блу Медикел Дивайсиз Б.В. | Endoluminal prosthesis containing medical agent |
US8021331B2 (en) | 2003-09-15 | 2011-09-20 | Atrium Medical Corporation | Method of coating a folded medical device |
US6996952B2 (en) | 2003-09-30 | 2006-02-14 | Codman & Shurtleff, Inc. | Method for improving stability and effectivity of a drug-device combination product |
US7192440B2 (en) * | 2003-10-15 | 2007-03-20 | Xtent, Inc. | Implantable stent delivery devices and methods |
GB0326180D0 (en) | 2003-11-11 | 2003-12-17 | Leuven K U Res & Dev | Biocompatible coating of medical devices |
KR20070010115A (en) | 2003-11-13 | 2007-01-22 | 알자 코포레이션 | Composition and apparatus for transdermal delivery |
US20050112170A1 (en) | 2003-11-20 | 2005-05-26 | Hossainy Syed F. | Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same |
AU2004293463A1 (en) | 2003-11-20 | 2005-06-09 | Angiotech International Ag | Implantable sensors and implantable pumps and anti-scarring agents |
US20050113849A1 (en) | 2003-11-26 | 2005-05-26 | Nicholas Popadiuk | Prosthetic repair device |
US8747881B2 (en) | 2003-12-19 | 2014-06-10 | Cordis Corporation | Intraluminal medical devices in combination with therapeutic agents |
US7303758B2 (en) | 2004-01-20 | 2007-12-04 | Cordis Corporation | Local vascular delivery of mycophenolic acid in combination with rapamycin to prevent restenosis following vascular injury |
US20050268573A1 (en) | 2004-01-20 | 2005-12-08 | Avantec Vascular Corporation | Package of sensitive articles |
US20050159809A1 (en) | 2004-01-21 | 2005-07-21 | Medtronic Vascular, Inc. | Implantable medical devices for treating or preventing restenosis |
US7211108B2 (en) | 2004-01-23 | 2007-05-01 | Icon Medical Corp. | Vascular grafts with amphiphilic block copolymer coatings |
US7806924B2 (en) * | 2004-02-18 | 2010-10-05 | Cordis Corporation | Implantable structures for local vascular delivery of cladribine in combination with rapamycin for restenosis |
DE112005001005A5 (en) * | 2004-02-28 | 2007-05-24 | Hemoteq Gmbh | Biocompatible coating, process and use of medical surfaces |
US7775965B2 (en) | 2004-03-09 | 2010-08-17 | The Board Of Regents Of The University Of Oklahoma | Decellularized grafts from umbilical cord vessels and process for preparing and using same |
US8075910B2 (en) | 2004-05-20 | 2011-12-13 | Pbm Pharmaceuticals, Inc. | Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions |
DE602005015975D1 (en) | 2004-05-25 | 2009-09-24 | Novamont Spa | USE OF PERFORATED BIODEGRADABLE FOILS AND HYGIENE PRODUCTS OBTAINED THEREFROM |
WO2005115341A2 (en) * | 2004-05-27 | 2005-12-08 | Advanced Bionutrition Corporation | Microparticles for oral delivery |
EP1793873B1 (en) | 2004-08-03 | 2013-08-07 | Tissuemed Limited | Tissue-adhesive materials |
US20070292478A1 (en) | 2004-08-30 | 2007-12-20 | Popowski Youri | Medical Implant Provided with Inhibitors of Atp Synthesis |
US20060058737A1 (en) * | 2004-09-16 | 2006-03-16 | Herweck Steve A | Catheter treatment stylet |
US20060058881A1 (en) | 2004-09-16 | 2006-03-16 | Trieu Hai H | Intervertebral disc nucleus implants and methods |
US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
WO2006036967A1 (en) | 2004-09-28 | 2006-04-06 | Atrium Medical Corporation | Solubilizing a drug for use in a coating |
WO2006036970A2 (en) | 2004-09-28 | 2006-04-06 | Atrium Medical Corporation | Method of thickening a coating using a drug |
US8367099B2 (en) | 2004-09-28 | 2013-02-05 | Atrium Medical Corporation | Perforated fatty acid films |
US9801982B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Implantable barrier device |
US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US8962023B2 (en) | 2004-09-28 | 2015-02-24 | Atrium Medical Corporation | UV cured gel and method of making |
US8312836B2 (en) | 2004-09-28 | 2012-11-20 | Atrium Medical Corporation | Method and apparatus for application of a fresh coating on a medical device |
US20090011116A1 (en) | 2004-09-28 | 2009-01-08 | Atrium Medical Corporation | Reducing template with coating receptacle containing a medical device to be coated |
US20060093643A1 (en) | 2004-11-04 | 2006-05-04 | Stenzel Eric B | Medical device for delivering therapeutic agents over different time periods |
US7727554B2 (en) * | 2004-12-21 | 2010-06-01 | Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center | Sustained-release nanoparticle compositions and methods for using the same |
TWI244270B (en) | 2005-01-17 | 2005-11-21 | Novatek Microelectronics Corp | Digital-to-analog converter |
CA2601156A1 (en) | 2005-03-22 | 2006-09-28 | Tyco Healthcare Group Lp | Bioactive wide-weave mesh |
US8747882B2 (en) | 2005-04-21 | 2014-06-10 | Astra Tech Ab | Catheter assembly with bactericidal effect |
US8414907B2 (en) | 2005-04-28 | 2013-04-09 | Warsaw Orthopedic, Inc. | Coatings on medical implants to guide soft tissue healing |
BRPI0613631A8 (en) | 2005-07-18 | 2017-12-26 | Univ Massachusetts Lowell | nanoemulsion and method, |
US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
US8574627B2 (en) | 2006-11-06 | 2013-11-05 | Atrium Medical Corporation | Coated surgical mesh |
US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
WO2007047028A1 (en) | 2005-10-14 | 2007-04-26 | Atrium Medical Corporation | Packaging and sterilization of medical devices |
EP1933991A4 (en) | 2005-10-15 | 2012-05-02 | Atrium Medical Corp | Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings |
US20070093894A1 (en) | 2005-10-25 | 2007-04-26 | Baylor College Of Medicine | Incorporation of antimicrobial combinations onto devices to reduce infection |
US10029034B2 (en) | 2005-12-15 | 2018-07-24 | CARDINAL HEALTH SWITZERLAND 515 GmbH | Drug-eluting articles with improved drug release profiles |
US8784886B2 (en) | 2006-03-09 | 2014-07-22 | GlaxoSmithKline, LLC | Coating capsules with active pharmaceutical ingredients |
US20070280986A1 (en) | 2006-06-01 | 2007-12-06 | Carlos Gil | Intra-operative coating of implants |
US20070299538A1 (en) | 2006-06-26 | 2007-12-27 | Roeber Peter J | Ease of use tissue repair patch |
US7892593B2 (en) | 2006-06-27 | 2011-02-22 | Ingo Werner Scheer | Process for coating a substrate |
WO2008016664A2 (en) | 2006-08-02 | 2008-02-07 | University Of Massachusetts Lowell | Compositions and methods for treating cancer with dacarbazine nanoemulsions |
KR101272976B1 (en) | 2006-09-19 | 2013-06-10 | (주)아모레퍼시픽 | Coating Composition for Oral Administration |
US9289279B2 (en) | 2006-10-06 | 2016-03-22 | Promethean Surgical Devices, Llc | Apparatus and method for limiting surgical adhesions |
US9492596B2 (en) | 2006-11-06 | 2016-11-15 | Atrium Medical Corporation | Barrier layer with underlying medical device and one or more reinforcing support structures |
US8906502B2 (en) | 2006-12-29 | 2014-12-09 | Ccp Composites Us Llc | Organic powder useful as the replacement of mineral filler in composites |
MX2010003364A (en) | 2007-10-08 | 2010-07-06 | Lux Biosciences Inc | Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors. |
CA2711174A1 (en) | 2007-12-31 | 2009-07-16 | Acclarent, Inc. | Mucosal tissue dressing and method of use |
US20110045050A1 (en) | 2009-08-24 | 2011-02-24 | Atrium Medical Corporation | Nanoemulsion formulations for direct delivery |
WO2012009707A2 (en) | 2010-07-16 | 2012-01-19 | Atrium Medical Corporation | Composition and methods for altering the rate of hydrolysis of cured oil-based materials |
-
2005
- 2005-09-28 WO PCT/US2005/034610 patent/WO2006036967A1/en active Application Filing
- 2005-09-28 US US11/238,554 patent/US8001922B2/en not_active Expired - Fee Related
- 2005-09-28 EP EP05804960.2A patent/EP1804717A4/en not_active Withdrawn
- 2005-09-28 WO PCT/US2005/034836 patent/WO2006037049A2/en active Application Filing
- 2005-09-28 US US11/236,908 patent/US8263102B2/en active Active
- 2005-09-28 WO PCT/US2005/034679 patent/WO2006036982A2/en active Application Filing
- 2005-09-28 WO PCT/US2005/034681 patent/WO2006036983A2/en active Application Filing
- 2005-09-28 US US11/239,555 patent/US20060067977A1/en not_active Abandoned
- 2005-09-28 US US11/236,977 patent/US20060088596A1/en not_active Abandoned
-
2011
- 2011-07-18 US US13/185,135 patent/US8722132B2/en not_active Expired - Fee Related
-
2012
- 2012-08-24 US US13/593,656 patent/US8722077B2/en not_active Expired - Fee Related
-
2014
- 2014-04-14 US US14/252,671 patent/US9682175B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3967728A (en) * | 1973-03-02 | 1976-07-06 | International Paper Company | Catheter package |
US5403283A (en) * | 1993-10-28 | 1995-04-04 | Luther Medical Products, Inc. | Percutaneous port catheter assembly and method of use |
US6152944A (en) * | 1997-03-05 | 2000-11-28 | Scimed Life Systems, Inc. | Catheter with removable balloon protector and stent delivery system with removable stent protector |
US20020012741A1 (en) * | 2000-07-28 | 2002-01-31 | Jochen Heinz | Process and apparatus for applying a thermally attached lubricating coating on an interior wall of a cylindrical container for medicinal purposes |
US20020116045A1 (en) * | 2001-02-22 | 2002-08-22 | Eidenschink Tracee E.J. | Crimpable balloon/stent protector |
US6565659B1 (en) * | 2001-06-28 | 2003-05-20 | Advanced Cardiovascular Systems, Inc. | Stent mounting assembly and a method of using the same to coat a stent |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9126025B2 (en) | 2008-05-01 | 2015-09-08 | Bayer Intellectual Property Gmbh | Method of coating a folded catheter balloon |
US9724497B2 (en) | 2008-05-01 | 2017-08-08 | Bayer Intellectual Property Gmbh | Method of coating a catheter balloon having a fold |
Also Published As
Publication number | Publication date |
---|---|
US8263102B2 (en) | 2012-09-11 |
US20120315219A1 (en) | 2012-12-13 |
WO2006036967A1 (en) | 2006-04-06 |
WO2006036983A3 (en) | 2006-09-14 |
US8722077B2 (en) | 2014-05-13 |
US8722132B2 (en) | 2014-05-13 |
US8001922B2 (en) | 2011-08-23 |
WO2006037049A3 (en) | 2006-08-31 |
US20060121081A1 (en) | 2006-06-08 |
WO2006036982A3 (en) | 2014-10-16 |
US20060067977A1 (en) | 2006-03-30 |
US20110274823A1 (en) | 2011-11-10 |
EP1804717A2 (en) | 2007-07-11 |
US20060088596A1 (en) | 2006-04-27 |
WO2006036982A2 (en) | 2006-04-06 |
US20140308333A1 (en) | 2014-10-16 |
WO2006036983A2 (en) | 2006-04-06 |
EP1804717A4 (en) | 2015-11-18 |
US9682175B2 (en) | 2017-06-20 |
US20060067974A1 (en) | 2006-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006037049A2 (en) | Application of a coating on a medical device | |
US8312836B2 (en) | Method and apparatus for application of a fresh coating on a medical device | |
EP1819297B1 (en) | Uv cured gel and method of making | |
EP2083875B1 (en) | Coated surgical mesh | |
US20060083768A1 (en) | Method of thickening a coating using a drug | |
EP2183002A1 (en) | Method and apparatus for application of a fresh coating on a medical device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 05800825 Country of ref document: EP Kind code of ref document: A2 |